documents incorporated reference portions proxy statement registrants annual meeting stockholders held may incorporated reference part iii annual report part item business general bristolmyers squibb company may referred bristolmyers squibb bms company us incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger engaged discovery development licensing manufacturing marketing distribution sale biopharmaceutical products global basis last years executed strategy transform next generation biopharmaceutical company transformation encompassed areas business operations part strategy divested nonpharmaceutical businesses implemented acquisition licensing strategy known stringofpearls executed productivity transformation initiative pti divestitures included medical imaging january convatec august mead johnson december acquisition licensing transactions included kosan biosciences inc june medarex inc medarex september zymogenetics inc zymogenetics october amira pharmaceuticals inc amira september inhibitex inc inhibitex february amylin pharmaceuticals inc amylin august well several license collaboration arrangements continue review cost structure intent maintain modernized efficient robust balance building competitive advantages securing innovative products planning future operate one segmentbiopharmaceuticals additional information business segments see item financial statementsnote business segment information compete worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession manufacture products united states us puerto rico foreign countries percentage total net sales significant region follows year ended december dollars millions united states europe japan china canada net sales products pharmaceutical products include chemicallysynthesized drugs small molecules increasing portion products produced biological processes typically involving recombinant dna technology called biologics small molecule drugs typically administered orally eg form pill tablet although drug delivery mechanisms used well biologics typically administered patients injections infusion revenues come products following therapeutic classes cardiovascular virology including human immunodeficiency virus hiv infection oncology neuroscience immunoscience metabolics pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity business focused innovative biopharmaceutical products rely patent rights various forms regulatory protection maintain market exclusivity products us european union eu countries patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product discussion patent rights regulatory forms exclusivity see intellectual property product exclusivity discussion impact generic competition business see generic competition following chart shows key products together year earliest basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us eu japan canada also sell pharmaceutical products countries however data provided countrybycountry basis individual country sales significant outside us eu japan china canada many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication one approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical trial data obtain marketing approval prior expiration data exclusivity estimate market exclusivity period products purposes business planning length market exclusivity products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate following schedule presents net sales key products estimated basic exclusivity loss us eu japanese chinese canadian markets net sales products past currently estimated year basic exclusivity loss dollars millions us eu japan china canada key products plavix b avaproavalide eliquis na abilify c e reyataz f sustiva franchise g h baraclude erbitux j k k sprycel yervoy na k k orencia k k l nulojix na onglyzakombiglyze byetta na na e e e bydureon na na n e e forxiga na na note currently estimated earliest year basic exclusivity loss includes statutory extensions exclusivity granted instances may able obtain additional six months exclusivity product based pediatric extension certain instances may laterexpiring patents cover particular forms compositions drug well methods manufacturing methods using drug patents may sometimes result favorable market position products product exclusivity predicted assured us healthcare law enacted qualifying biologic products receive years data exclusivity biosimilar enter market described detail intellectual property product exclusivity indicates brand names products trademarks owned wholly owned bms specific trademark ownership information included currently market product country region indicated uncertainty chinas exclusivity laws resulted generic competition china market references eu throughout include member states european union year ended december basic patent applications filed current member states listed products instances date basic exclusivity loss different various eu member states eu countries basic patent obtained may data protection available b data exclusivity eu expired july major markets within europe product national patents expiring specifically claim bisulfate form clopidogrel however generic alternate salt forms clopidogrel bisulfate marketed compete plavix throughout eu c rights commercialize abilify aripiprazole us terminate rights commercialize abilify eu terminate e exclusivity period based regulatory data protection f data exclusivity eu expires g exclusivity period relates sustiva brand include exclusivity related combination therapy composition matter patent efavirenz us expires method use patent treatment hiv infection expires pediatric exclusivity granted provides additional six month period exclusivity added term patents listed orange book h exclusivity period relates sustiva brand include exclusivity related combination therapy market exclusivity sustiva expected expire countries eu data exclusivity sustiva expired eu february us district court district delaware invalidated composition matter patent covering baraclude scheduled expire may face generic competition product beginning j biologic product approved biologics license application bla data exclusivity us expires patent specifically claims composition matter cetuximab active ingredient erbitux rights commercialize cetuximab terminate k exclusivity period based regulatory data protection l data exclusivity canada expires exclusivity period based method use patent composition matter patent expired n exclusivity period based formulation patents summary indication intellectual property position product partner thirdparty manufacturing arrangements products us applicable eu japan canada plavix plavix clopidogrel bisulfate platelet aggregation inhibitor approved protection fatal nonfatal heart attack stroke patients history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codeveloped jointly marketed sanofi october bms sanofi announced restructuring alliance following loss exclusivity plavix avaproavalide many major markets information alliance sanofi restructuring see strategic alliances collaborations item financial statementsnote alliances collaborations composition matter patent us expired may eu regulatory data exclusivity protection expired july major markets within europe plavix benefits national patents expiring specifically claim bisulfate form clopidogrel however generic alternative salt forms clopidogrel bisulfate marketed compete throughout eu obtain bulk requirements clopidogrel bisulfate sanofi prior january company sanofi finished product respective facilities effective january company longer finish clopidogrel bisulfate facilities avaproavalide avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy irbesartan codeveloped jointly marketed sanofi end october bms sanofi announced restructuring alliance following loss exclusivity plavix avaproavalide many major markets information alliance sanofi restructuring see strategic alliances collaborations item financial statementsnote alliances collaborations composition matter patent us expired march expires countries eu data exclusivity eu expired august avapro october avalide composition matter patent expired canada march irbesartan manufactured company sanofi manufacture bulk requirements irbesartan finish avaproavalide facilities avalide purchase bulk requirements hydrochlorothiazide thirdparty alliance restructuring bmss manufacturing obligations phase sanofi assuming companys manufacturing supply obligations irbesartan products end eliquis eliquis apixaban oral factor xa inhibitor targeted stroke prevention atrial fibrillation prevention treatment venous thromboembolic vte disorders currently approved eu canada japan prevention stroke systemic embolism adult patients nonvalvular atrial fibrillation nvaf one risk factors use vte prevention adult patients undergone elective hip knee surgery december us food drug administration fda approved eliquis reduce risk stroke systemic embolism patients nvaf apixaban discovered internally part alliance pfizer inc pfizer information alliance pfizer see item financial statementsnote alliances collaborations composition matter patent covering apixaban us expires february excluding potential patent term extensions eu expires applied supplementary protection certificates supplementary protection certificates granted expire data exclusivity eu expires composition matter patent expires canada apixaban manufactured company thirdparty product finished facilities abilify abilify aripiprazole atypical antipsychotic agent adult patients schizophrenia bipolar mania disorder major depressive disorder abilify also pediatric uses schizophrenia bipolar disorder among others global commercialization agreement otsuka pharmaceutical co ltd otsuka except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt information arrangement otsuka see strategic alliances collaborations item financial statementsnote alliances collaborations basic us composition matter patent covering aripiprazole term current abilify agreement expire april including granted patent term extension six month pediatric extension composition matter patent force germany united kingdom uk france italy netherlands romania sweden switzerland spain denmark original expiration date extended grant supplementary protection certificate countries except romania denmark data exclusivity rights commercialize eu expire data exclusivity canada expires obtain bulk requirements aripiprazole otsuka company otsuka finish product respective facilities reyataz reyataz atazanavir sulfate protease inhibitor treatment human immunodeficiency virus hiv developed atazanavir worldwide license novartis pharmaceutical corporation novartis royalty paid based percentage net sales entitled promote reyataz use combination norvir ritonavir non exclusive license agreement abbott laboratories amended royalty paid based percentage net sales licensing agreement gilead sciences inc gilead develop commercialize fixeddose combination containing reyataz one gileads compounds development market exclusivity reyataz expected expire us canada china major eu member countries japan data exclusivity eu expires manufacture bulk requirements atazanavir finish product facilities sustiva franchise sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise includes sustiva antiretroviral drug used treatment hiv well bulk efavirenz included combination therapy atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen combining sustiva gileads truvada emtricitabine tenofovir disoproxil fumarate atripla first complete highly active antiretroviral therapy treatment product hiv available us fixeddose combination taken daily fixeddose combinations contain multiple medicines formulated together help simplify hiv therapy patients providers information arrangement gilead see strategic alliances collaborations item financial statementsnote alliances collaborations rights market efavirenz us canada uk france germany ireland italy spain licensed merck co inc royalty based percentage net sales composition matter patent efavirenz us expires method use patent treatment hiv infection expires additional six month period pediatric exclusivity added term patents market exclusivity sustiva expected expire countries eu canada data exclusivity sustiva expired eu another company market efavirenz japan certain atripla patents subject patent litigation us time us patents covering efavirenz composition matter method use challenged eu patent efavirenz subject litigation netherlands germany uk information litigation matters see item financial statementsnote legal proceedings contingencies obtain bulk requirements efavirenz third parties produce finished goods facilities supply third parties bulk efavirenz gilead responsible producing finished atripla product baraclude baraclude entecavir potent selective inhibitor hepatitis b virus approved fda treatment chronic hepatitis b infection baraclude discovered developed internally also approved marketed countries outside us including china japan eu february us district court district delaware invalidated composition matter patent covering baraclude scheduled expire may face generic competition product beginning information patent litigation matter see item financial statementsnote legal proceedings contingencies composition matter patent expires eu japan composition matter patent expired canada uncertainty chinas exclusivity laws resulted generic competition china market entecavir manufactured company thirdparty product finished facilities erbitux erbitux cetuximab igg monoclonal antibody designed exclusively target block epidermal growth factor receptor egfr expressed surface certain cancer cells multiple tumor types well normal cells erbitux biological product approved treatment combination irinotecan treatment patients egfr expressing metastatic colorectal cancer mcrc failed irinotecanbased regimen monotherapy patients intolerant irinotecan fda also approved erbitux use treatment squamous cell carcinoma head neck specifically erbitux approved use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patients recurrent metastatic squamous cell carcinoma head neck prior platinumbased therapy failed fda also approved erbitux firstline recurrent locoregional metastatic head neck cancer combination platinumbased chemotherapy fluorouracil erbitux marketed north america us agreement imclone systems incorporated imclone predecessor company imclone llc whollyowned subsidiary eli lilly company lilly share copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement signed october imclone merck kgaa merck serono japan erbitux received marketing approval japan july use treating patients advanced recurrent colorectal cancer description alliance imclone see strategic alliances collaborations item financial statementsnote alliances collaborations data exclusivity us expires patent specifically claims composition matter cetuximab active molecule erbitux erbitux approved fda health authorities monotherapy use patent use erbitux combination antineoplastic agent approved fda combination use claimed granted us patent expires including granted patent term extension inventorship use patent challenged three researchers yeda research development company ltd yeda pursuant settlement agreement executed announced december imclone sanofi yeda end worldwide litigation related use patent sanofi yeda granted imclone worldwide license use patent data exclusivity japan canada expire yeda right license use patent others yedas license patent third parties could result product competition erbitux might otherwise occur unable assess whether extent competitive impact occur quantify impact however yeda granted amgen inc amgen license use patent amgen received fda approval market egfrproduct competes erbitux obtain finished goods requirements cetuximab use north america lilly lilly manufactures bulk requirements cetuximab facilities filling finishing performed thirdparty bms oversight responsibility description supply agreement lilly see manufacturing quality assurance sprycel sprycel dasatinib multitargeted tyrosine kinase inhibitor approved treatment adults phases chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib mesylate treatment adults philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy fda approved sprycel treatment adult patients newly diagnosed philadelphia chromosomepositive ph chronic myeloid leukemia cml chronic phase sprycel internally discovered part strategic alliance otsuka information alliance otsuka see strategic alliances collaborations item financial statementsnote alliances collaborations patent term extension granted us extending term basic composition matter patent covering dasatinib june dasatinib subject patent litigation us information litigation matter see item financial statementsnote legal proceedings contingencies us orphan drug exclusivity expires protects product generic applications currently approved orphan indications majority eu countries composition matter patent covering dasatanib expires april excluding potential term extensions composition matter patent expires japan canada china manufacture bulk requirements dasatinib finish product facilities yervoy yervoy ipilimumab biological product monoclonal antibody treatment patients unresectable inoperable metastatic melanoma ipilimumab approved us march eu july currently also studied indications including lung cancer well adjuvant melanoma hormonerefractory prostate cancer information research development yervoy see research development yervoy discovered medarex codeveloped company medarex subsidiary patent covering ipilimumab composition matter currently expires us eu excluding potential patent term extensions canada data exclusivity expires us eu obtain bulk ipilimumab thirdparty manufacturer finish product third party facility orencia orencia abatacept biological product fusion protein novel immunosuppressive activity targeted initially adult patients moderate severe rheumatoid arthritis inadequate response certain currently available treatments abatacept available intravenous formulation beginning subcutaneous formulation us orencia discovered developed internally series patents covering abatacept method use us patent term extension granted one composition matter patents extending term us patent majority eu countries patent covering abatacept expires applied supplementary protection certificates also pediatric extension supplementary protection certificates protection protection certificates granted data exclusivity expires canada us eu japan obtain bulk abatacept thirdparty manufacturer also manufacture bulk facility finish product facilities formulations nulojix nulojix belatacept biological product fusion protein novel immunosuppressive activity prevention kidney transplant rejection approved launched us june approved eu june launched july belatacept internally discovered developed patent covering belatacept composition matter expires april us may eu data exclusivity expires us june eu june manufacture bulk requirements belatacept finish products facilities onglyza kombiglyze onglyza saxagliptin dipeptidyl peptidase inhibitor oral compound indicated treatment type diabetes adjunct diet exercise kombiglyze saxagliptin metformin hydrochloride extendedrelease approved us combination product indicated adjunct diet exercise improve glycemic control adults type diabetes mellitus treatment saxagliptin metformin appropriate komboglyze saxagliptin metformin immediaterelease approved eu combination product indicated adjunct diet exercise improve glycemic control adults type diabetes mellitus inadequately controlled maximally tolerated dose metformin alone already treated combination saxagliptin metformin separate tablets document unless specifically noted refer kombiglyze komboglyze kombiglyze onglyza internally discovered company kombiglyze codeveloped company astrazeneca plc astrazeneca worldwide except japan codevelopment cocommercialization agreement astrazeneca saxagliptin information arrangement astrazeneca otsuka japan see strategic alliances collaborations item financial statementsnote alliances collaborations patent covering saxagliptin composition matter expires march us eu canada market exclusivity china expires manufacture bulk requirements saxagliptin facilities obtain bulk metformin kombiglyze third party company astrazeneca finish onglyza facilities company finishes kombiglyze facility byetta byettaexenatide twice daily glucagonlike peptide glp receptor agonist treatment type diabetes byetta acquired amylin acquisition august byetta internally discovered amylin whollyowned subsidiary company worldwide development commercialization agreement astrazeneca byetta also agreement lilly regarding termination collaboration global development commercialization byetta bydureon company lilly process transferring rights company astrazeneca information arrangement astrazeneca see strategic alliances collaborations item financial statementsnote alliances collaborations composition matter patent covering exenatide expired method use patent expires us data exclusivity expires europe japan canada obtain bulk requirements exenatide third parties manufacturing finishing also takes place third party facilities bydureon bydureon exenatide extendedrelease injectable suspension onceweekly glp receptor agonist treatment type diabetes bydureon acquired amylin acquisition august bydureon internally discovered amylin whollyowned subsidiary company worldwide development commercialization agreement astrazeneca bydureon information arrangement astrazeneca see strategic alliances collaborations item financial statementsnote alliances collaborations formulation patents expire us data exclusivity expires europe japan bulk requirements exenatide obtained third parties microspheres manufacturing process required extended release formulation performed company finish product facilities forxiga forxiga dapagliflozin oral sodiumglucose cotransporter sglt treatment diabetes approved eu november adjunct diet exercise combination glucoselowering medicinal products including insulin monotherapy metforminintolerant patients currently registrational review process us discussion see item managements discussion analysis financial condition results operations product pipeline developments forxiga internally discovered worldwide codevelopment cocommercialization agreement astrazeneca dapagliflozin patent covering dapagliflozin composition matter expires october us may eu manufacture bulk requirements dapagliflozin finish product facilities research development invest heavily research development rd believe critical longterm competitiveness major rd facilities princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development also carried various facilities throughout world including belgium uk india sites us supplement internal drug discovery development programs alliances collaborative agreements agreements bring new products pipeline help us remain cutting edge technology search novel medicines drug development engage services physicians hospitals medical schools research organizations worldwide conduct clinical trials establish safety effectiveness new products management continues emphasize leadership innovation productivity quality strategies success research development activities concentrate biopharmaceutical research development efforts following disease areas significant unmet medical need affective psychiatric disorders alzheimersdementia cardiovascular diabetes hepatitis hivacquired immunodeficiency syndrome aids oncology immunologic disorders fibrotic disease also continue analyze may selectively pursue promising leads areas addition discovering developing new molecular entities look ways expand value existing products new indications formulations provide additional benefits patients order new drug reach market industry practice government regulations us eu foreign countries provide determination drugs effectiveness safety preclinical tests controlled clinical evaluation clinical development potential new drug includes phase phase ii phase iii clinical trials designed specifically support new drug application particular indication assuming trials successful phase clinical trials involve small number healthy patients patients suffering indicated disease test safety proper dosing phase ii clinical trials involve larger patient population investigate side effects efficacy optimal dosage drug candidate phase iii clinical trials conducted confirm phase ii results significantly larger patient population longer term provide reliable conclusive data regarding safety efficacy drug candidate rd process typically takes thirteen years longer nearly three years often spent phase iii latestage development consider rd programs phase iii latestage development significant rd programs programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations drug development time consuming expensive risky average one chemical compounds discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval according kmr group based industry success rates approximately compounds enter phase development fail achieve regulatory approval failure rate compounds enter phase ii development approximately compounds enter phase iii development approximately total research development expenses include costs discovery research preclinical development early lateclinical development drug formulation well postcommercialization medical support marketed products proportionate allocations enterprisewide costs appropriate costs research development spending billion billion billion includes payments thirdparty collaborations contracts end employed approximately people rd activities including substantial number physicians scientists holding graduate postgraduate degrees higherskilled technical personnel manage rd programs portfolio basis investing resources stage research development early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth company spending latestage development programs represents approximately annual rd expenses individual investigational compound marketed product represented rd expenses last three years listed several latestage investigational compounds phase iii clinical trials least one potential indication whether investigational compounds ultimately becomes one marketed products depends results clinical studies competitive landscape potential products market manufacturing processes necessary produce potential product commercial scale among factors however noted assurance seek regulatory approval compounds approval sought obtained also assurance compound approved commercially successful stage development determine intellectual property issues patent protection may may available investigational compounds patent coverage highlighted includes patent term extensions granted asunaprevir asunaprevir oral small molecule ns protease inhibitor phase iii development commenced treatment hepatitis c virus infection patent covering asunaprevir composition matter expires us daclatasvir daclatasvir oral small molecule nsa replication complex inhibitor phase iii development commenced treatment hepatitis c virus infection patent covering daclatasvir composition matter expires us peginterferon lambda peginterferon lambda novel type interferon phase iii development commenced hepatitis c virus infection patent covering peginterferon lambda composition matter expires us elotuzumab elotuzumab humanized monoclonal antibody investigated anticancer treatment discovered pdl biopharma became part facet biotech corporation facet spinoff facet subsequently acquired abbott laboratories abbott became part abbvie inc abbvie following spinoff abbott elotuzumab part alliance abbvie phase iii trials commenced multiple myeloma abbvie owns patent covering elotuzumab composition matter expires us nivolumab nivolumab fully human monoclonal antibody binds programmed death receptor pd nkt cells investigated anticancer treatment phase iii trials commenced non small cell lung cancer renal cell cancer melanoma patent covering nivolumab composition matter expires us metreleptin metreleptin acquired part amylin acquisition codeveloped astrazeneca metreleptin protein development treatment lipodystrophy currently registrational process patent covering metreleptin composition matter expires us data exclusivity us expire years regulatory approval provided notice termination global codevelopment cocommercialization arrangement necitumumab imcf fully human monoclonal antibody investigated anticancer treatment discovered imclone part alliance company lilly rights returning lilly termination effective may though lilly may terminate earlier terminated development program brivanib phase iii trials anticancer treatment potential use hepatocellular carcinoma colorectal cancer following table lists potential additional indications andor formulations key marketed products phase iii development currently regulatory review key marketed product potential indication andor formulation eliquis additional indication vte treatment reyataz pediatric extension baraclude pediatric extension erbitux additional indication esophageal cancer yervoy additional indications adjuvant melanoma prostate cancer nonsmall cell lung cancer small cell lung cancer additional indication firstline metastatic melanoma eu orencia additional indication lupus nephritis additional formulation subcutaneous japan onglyza additional use cardiovascular risk reduction pediatric extension bydureon dual chamber pen weekly suspension forxiga fixed dose combination metformin following key developments currently expected occur respect significant pipeline programs outcome timing expected developments dependent upon number factors including among things availability data outcome certain clinical trials acceptance presentations certain medical meetings andor actions health authorities undertake obligation publicly update information whether result new information future events otherwise eliquis data available phase iii study vte treatment daclatasvir data available phase iii hepatitis c virus infection combination studies asunaprevir data available phase iii hepatitis c virus infection combination studies sprycel data available phase iii study prostate cancer four year data available first line cml yervoy data available phase iii study prostate cancer orencia phase iii start psoriatic arthritis nulojix five year data available phase iii studies prevention kidney transplant rejection onglyza data available cardiovascular risk reduction study bydureon planned submission dual chamber pen us europe forxiga planned resubmission us treatment type diabetes data available phase iii blood pressure studies two year data available phase iii studies diabetic patients history cardiovascular disease metreleptin planned us submission treatment lipodystrophy strategic alliances collaborations enter strategic alliances collaborations third parties transfer rights develop manufacture market andor sell pharmaceutical products owned parties alliances collaborations include licensing arrangements codevelopment comarketing agreements copromotion arrangements joint ventures alliances arrangements reduce risk incurring research development expenses compounds lead revenue generating products however profitability alliance products generally lower profits alliance products shared alliance partners actively pursue arrangements view alliances important complement discovery development activities strategic alliances arrangements third parties rights manufacture market andor sell pharmaceutical products contain customary early termination provisions typically found agreements kind generally based partys material breach bankruptcy voluntary involuntary product safety concerns amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination upon days notice generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured number alliance agreements also permit collaborator us terminate without cause typically exercisable substantial advance written notice often exercisable specified period time elapsed collaboration agreement signed strategic alliances arrangements typically otherwise contain provisions provide party right terminate alliance short notice general retain rights product brought alliance another party partys intellectual property alliance terminates loss rights one products marketed sold us pursuant strategic alliance arrangement could material results operations cash flows case plavix abilify could material financial condition liquidity customary pharmaceutical industry terms strategic alliances arrangements generally coextensive exclusivity period may vary countrybycountry basis significant current alliances arrangements currently marketed products investigational compounds described current marketed productsinlicensed sanofi september bms sanofi restructured terms codevelopment cocommercialization agreements discussed effective january subject certain countries receipt regulatory approvals sanofi assume worldwide operations alliance exception plavix us puerto rico alliance plavix two markets continue unchanged december terms original alliance arrangements bms return sanofi rights receive quarterly royalties january december terminal payment sanofi million end ongoing disputes companies resolved including onetime payment million bms sanofi related avalide supply disruption us accrued pursuant master restructuring agreement company various mechanisms depending territory return sanofi rights clopidogrel irbesartan markets exception clopidogrel us puerto rico company continue act operating partner majority controlling interest currently existing local arrangements territory territory b exception clopidogrel us puerto rico terminated mutual agreement products continue sold local country entities territories addition sanofi assume marketing authorizations products extent currently held company affiliates result sanofi assume control activities relating distribution commercialization medical affairs clopidogrel irbesartan regions pursuant master restructuring agreement related alliance agreements sanofi assume companys manufacturing supply obligations irbesartan products end company manufacture bulk clopidogrel longer finish clopidogrel products facilities company retain rights intellectual property developed alliance necessary fulfill continuing obligations alliance arrangements master restructuring agreement related alliance agreements alliance remain effect december sanofis payment terminal fee exception us puerto rico alliance remain effect december agreements sanofi codevelopment cocommercialization avaproavalide plavix avaproavalide copromoted certain countries outside us tradename aprovelcoaprovel comarketed certain countries outside us us tradename karveakarvezide plavix copromoted certain countries outside us tradename plavix comarketed certain countries outside us us tradename iscover prior worldwide alliance operated framework two geographic territories one covering certain european asian countries referred territory one covering us puerto rico canada australia certain latin american countries referred territory b territory b managed two separate sets agreements one plavix us puerto rico products australia mexico brazil colombia argentina separate set agreements avaproavalide us puerto rico within territory territory partnership existed supply finished product country within territory manage contract certain central expenses marketing research development royalties countries within territories b structured local affiliate sanofis local affiliate either comarket separate brands ie affiliate operated independently competed selling product different trademarks copromoted single brand ie product trademark within territory comarketing countries include germany spain italy irbesartan greece china clopidogrel bisulfate sold iscover karveakarvezide sanofi sold plavix aprovelcoaprovel countries except china retained right currently comarket iscover company sanofi copromoted plavix aprovelcoaprovel france uk belgium netherlands switzerland portugal addition company sanofi copromoted plavix austria italy ireland denmark finland norway sweden taiwan south korea hong kong aprovelcoaprovel certain french export countries prior company sanofi also copromoted plavix singapore sanofi acted operating partner territory owned financial controlling interest territory ownership interest territory accounted investment partnership entities territory equity method recognized share results equity net income affiliates share net income partnership entities taxes million million million within territory b company sanofi copromoted plavix avaproavalide us canada puerto rico territory b countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing countries act operating partner territory b owned majority controlling interest territory consolidated partnership results territory b recognized sanofis share results net earnings attributable noncontrolling interest net taxes million million million recognized net sales territory b territory comarketing countries billion billion billion territory partnerships governed series committees enumerated functions powers responsibilities territory two senior committees final decisionmaking authority respect territory enumerated functions powers responsibilities within jurisdictions alliance arrangements may terminated sanofi us either whole affected country territory depending circumstances event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continues days order decree approving continues unstayed effect days ii material breach obligation major alliance agreement remains uncured days following notice breach except commencement diligent prosecution cure occurred within days notice iii deadlocks one senior committees render continued commercialization product impossible given country territory iv increase combined cost goods royalty exceeds specified percentage net selling price product v good faith determination terminating party commercialization product terminated reasons patient safety case termination rights agreements included provisions termination relevant alliance respect applicable product applicable country territory case termination due bankruptcy insolvency material breach products applicable territory termination procedures slightly different however events could lose rights either products applicable relevant country territory even case bankruptcy insolvency material breach defaulting party discussion strategic alliance sanofi see item financial statementsnote alliances collaborations otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify abilify agreement excluding certain asia pacific countries april company otsuka agreed extend us portion commercialization manufacturing agreement expected loss product exclusivity april contractual share abilify net sales recognized company pursuant extension uk germany france spain company receives thirdparty net sales countries us thirdparty customers invoiced company behalf otsuka alliance revenue recognized abilify shipped risks rewards ownership transferred third party customers also exclusive right sell abilify countries europe americas number countries asia countries recognize net sales terms abilify agreement amended purchase product otsuka perform finish manufacturing sale us otsuka third party customers terms extension agreement paid otsuka million amortized reduction net sales extension period unamortized balance included assets otsuka receives royalty based total us net sales included cost products sold otsuka responsible us expenses related commercialization abilify bms also receives additional reimbursement otsuka sales force costs incurred bms excess requirements specified agreement reimbursements netted principally marketing selling administrative advertising product promotion expenses abilify agreement expires april us june eu countries country exclusive right sell abilify agreement expires later april loss exclusivity country beginning january bms receive following percentages us annual net sales net sales initially recognized adjusted reflect actual level net sales share us net sales billion billion billion billion billion billion billion billion billion excess billion us commercialization agreement amended october requiring otsuka assume full responsibility providing funding sales force efforts effective january consideration bms paid otsuka million january responsible funding certain operating expenses million million million eu otsuka reimburse bms sales force effort provided march beginning april otsuka assume responsibility providing funding sales force effort us portion abilify agreement oncology agreement described include changeofcontrol provision acquired acquiring company competing product abilify new company assume abilify agreement amended oncology agreement currently exists acquiring company product competes abilify otsuka elect request acquiring company choose whether divest abilify competing product scenario abilify divested otsuka would obligated acquire rights abilify agreement amended price according predetermined schedule agreements also provide event generic competitor abilify option terminating abilify april amendment agreement previously amended remaining force exercise option either would receive payment otsuka according predetermined schedule oncology agreement would terminate time ii oncology agreement would continue truncated period according predetermined schedule early termination abilify agreement immediate upon notice case voluntary bankruptcy ii minimum payments made otsuka iii first commercial sale occurred within three months receipt necessary approvals days material breach occurred cured commencement cure occurred within days notice material breach days case involuntary bankruptcy petition filed dismissed addition termination available otsuka upon days notice event challenge otsukas patent rights marketbymarket basis event market product direct competition abilify upon termination expiration abilify agreement retain rights abilify recognized net sales abilify billion billion billion addition million extension payment total upfront milestone licensing payments made otsuka abilify agreement million discussion oncology agreement otsuka see current marketed productsinternally discovered discussion strategic alliance otsuka see item financial statementsnote alliances collaborations lilly egfr commercialization agreement lilly lillys subsidiary imclone codevelopment copromotion erbitux necitumumab imcf us canada japan information agreement respect necitumumab see investigational compounds developmentinlicensed egfr agreement respect erbitux sales north america lilly receives distribution fee based flat rate net sales north america plus reimbursement certain royalties paid lilly company lilly share one half profits losses evenly japan merck kgaa receiving half profits losses japan parties share royalties payable third parties pursuant formula set forth commercialization agreement purchase north american commercial requirements bulk erbitux lilly agreement expires erbitux north america september early termination available based material breach effective days notice material breach material breach cured commencement cure occurred upon six months notice us exists significant concern regarding regulatory patient safety issue would seriously impact longterm viability product upon termination expiration alliance retain rights erbitux share codevelopment copromotion rights erbitux merck kgaa japan agreement signed october expiring lilly merck kgaa merck japan lilly ability terminate agreement determines commercially unreasonable continue erbitux received marketing approval japan july use erbitux treating patients advanced recurrent colorectal cancer recognized net sales erbitux million million million discussion strategic alliance lilly see item financial statementsnote alliances collaborations gilead joint venture gilead develop commercialize atripla us canada europe company gilead share responsibility commercializing atripla us canada throughout eu certain european countries provide funding fieldbased sales representatives support promotional efforts atripla gilead recognizes atripla revenues us canada countries europe revenue efavirenz component determined applying percentage atripla revenue approximate revenue sustiva brand recognized efavirenz revenues billion billion billion related atripla net sales joint venture company gilead continue terminated mutual agreement parties otherwise described event material breach one party nonbreaching party may terminate joint venture parties agree desirable practicable withdraw combination product markets commercialized time one generic versions partys component products appear market us party right terminate joint venture thereby acquire rights combination product us canada however three years terminated party continue receive percentage net sales based contribution bulk components atripla otherwise retains rights products entered licensing agreement gilead develop commercialize fixeddose combination containing reyataz gileads cobicistat pharmacoenhancing boosting agent currently phase iii clinical trials increases blood levels certain hiv medicines potentially allow one pill daily dosing cobicstat currently registrational process fda discussion strategic alliance gilead see item financial statementsnote alliances collaborations current marketed productsinternally discovered astrazeneca january entered worldwide except japan codevelopment cocommercialization agreement astrazeneca onglyza saxagliptin agreement dapagliflozin sglt agreement kombiglyze codeveloped astrazeneca saxagliptin agreement exclusive rights develop sell onglyza japan licensed otsuka december june assigned otsuka kyowa hakko kirin khk described investigational compounds developmentinternally discovered manufacture onglyza kombiglyze certain limited exceptions recognize net sales key markets received million upfront milestone licensing payments astrazeneca meeting certain development regulatory milestones onglyza kombiglyze could receive additional million salesbased milestones met majority costs initial development plans paid astrazeneca additional development costs generally shared equally expense onglyza kombiglyze development costs net astrazenecas share research development two companies jointly develop clinical marketing strategy share commercialization expenses profits losses equally global basis excluding japan sglt agreement received million upfront milestone licensing payments astrazeneca including million received january could receive million development regulatory milestones dapagliflozin met additional million salesbased milestones dapagliflozin met majority costs initial plans paid astrazeneca additional development costs generally shared equally except japan astrazeneca bears substantially development costs prior approval first indication expense dapagliflozin development costs net alliance partners share research development sglt agreement like saxagliptin agreement two companies jointly develop clinical marketing strategy share commercialization expenses profits losses dapagliflozin equally global basis manufacture dapagliflozin certain limited exceptions recognize net sales key markets respect japan astrazeneca operational cost responsibility development regulatory activities behalf collaboration related certain trials development costs shared two companies two companies jointly market product japan sharing commercialization expenses activities splitting profits losses equally like rest world also manufacture dapagliflozin recognize net sales japan like rest world dapagliflozin currently studied phase ii clinical trials japan august bms astrazeneca pharmaceuticals lp whollyowned subsidiary astrazeneca entered collaboration regarding worldwide development commercialization amylins portfolio products including bydureon byetta symlin arrangement based framework existing diabetes alliance agreements onglyza forxiga discussed including equal sharing profits losses arising collaboration astrazeneca indicated intent establish equal governance rights certain key strategic financial decisions regarding collaboration pending required antitrust approvals certain international markets bms received preliminary proceeds billion astrazeneca consideration entering collaboration accounted deferred income amortized reduction cost products sold prorata basis estimated useful lives related longlived assets assigned purchase price allocation primarily intangible assets weightedaverage estimated useful life years property plant equipment weightedaverage estimated useful life years net proceeds bms receive astrazeneca consideration entering collaboration subject certain adjustments including right receive additional million astrazeneca exercises option equal governance rights bms astrazeneca agreed share certain tax attributes related amylin collaboration preliminary proceeds billion bms received astrazeneca included million related sharing certain tax attributes discussion strategic alliance astrazeneca see item financial statementsnote alliances collaborations investigational compounds development internally discovered otsuka simultaneously extension abilify agreement april company otsuka entered oncology agreement sprycel ixempra ixabepilone includes us japan eu markets oncology territory beginning collaboration fees pay otsuka annually following percentages aggregate net sales sprycel ixempra oncology territory net sales million million million million million million billion excess billion periods otsuka contribute first million certain commercial operational expenses relating oncology products oncology territory ii commercial operational expenses relating products oncology territory excess million beginning otsuka copromotes sprycel us japan exercised right copromote top five eu markets beginning january oncology agreement expires respect sprycel ixempra includes changeofcontrol provision acquired abilify agreement described discussion abilify agreement otsuka see current marketed productsinlicensed discussion strategic alliance otsuka see item financial statementsnote alliances collaborations pfizer company pfizer parties worldwide codevelopment cocommercialization agreement eliquis anticoagulant discovered us prevention treatment atrial fibrillation venous thromboembolic vte disorders pfizer funds development costs since january fund received million upfront milestone licensing payments pfizer date including million received february could receive additional million pfizer development regulatory milestones met companies jointly develop clinical marketing strategy eliquis share commercialization expenses profits losses equally global basis discussion strategic alliance pfizer see item financial statementsnote alliances collaborations investigational compounds developmentinlicensed lilly january company lilly restructured egfr commercialization agreement provide codevelopment cocommercialization necitumumab imcf fully human antibody currently phase iii development nonsmall cell lung cancer november bms provided notice termination collaboration agreement lilly necitumumab termination effective may though lilly may terminate earlier abbvie august granted exclusive rights facet biotech corporation abbvie codevelopment cocommercialization elotuzumab humanized monoclonal antibody investigated treatment multiple myeloma terms agreement fund development costs elotuzumab upon commercialization abbott share profits losses us paid tiered royalties outside us solely responsible commercialization elotuzumab addition abbott may receive milestone payments us based certain regulatory events sales thresholds achieved investigational compounds developmentinternally discovered otsuka january granted otsuka exclusive rights japan develop commercialize onglyza agreement entitled receive milestone payments based certain regulatory events well salesbased payments following regulatory approval onglyza japan retained rights copromote onglyza otsuka japan otsuka responsible development costs japan june otsuka assigned rights onglyza exception specific transition services khk part consent assignment bms waives rights copromote onglyza japan bms supply finished saxagliptin khk astrazeneca part collaboration astrazeneca bms astrazeneca codeveloping metreleptin treatment lipodystrophy currently registrational process japan metreleptin acquired bms part amylin acquisition please see astrazeneca description current marketed products internally discoveredand item financial statementsnote alliances collaborations information regarding collaboration collaborations february bms reckitt benckiser group plc rbl agreed enter license three year collaboration regarding several overthecounterproducts sold primarily mexico brazil transaction expected close first second quarter subject customary closing conditions regulatory approvals connection collaboration rbl responsible sales distribution marketing certain regulatory matters bms responsible exclusive supply products upon expiration collaboration rbl right purchase remaining assets business held bms price determined based multiple sales plus cost remaining inventory held bms time rbl would assume responsibility products though rbl may extend term supply agreement bms certain circumstances option exercised assets previously transferred rbl collaboration period revert back bms bms expected receive proceeds million start collaboration period allocated license rights transferred rbl written option february bms medicines company entered global license two year collaboration recothrom recombinant thrombin use topical hemostat control nonarterial bleeding surgical procedures previously acquired bms connection acquisition zymogenetics medicines company responsible sales distribution marketing regulatory matters relating recothrom bms responsible exclusive supply product bms received upfront payment million collaboration expires february time medicines company right purchase remaining assets business held bms price determined based multiple sales plus carrying cost inventory option exercised assets previously transferred medicines company collaboration period revert back bms addition strategic alliances described inlicensing outlicensing arrangements respect inlicenses agreements novartis reyataz among others based current expectations respect expiration market exclusivity significant markets licensing arrangements novartis reyataz expected expire us eu japan discussion market exclusivity protection including chart showing net sales key products together year basic exclusivity loss occurred expected occur us eu japan canada see products certain compounds outlicensed third parties development commercialization including obtained result acquisitions zymogenetics october medarex august entitled receive milestone payments compounds move regulatory process royalties based product sales products commercialized intellectual property product exclusivity license number patents us foreign countries primarily covering products also developed many brand names trademarks products consider overall protection patents trademarks licenses intellectual property rights material value act protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced regulatory intellectual property rights many developed countries provide certain nonpatent incentives development medicines example us eu japan canada certain markets regulatory intellectual property rights offered incentives research medicines rare diseases orphan drugs medicines useful treating pediatric patients incentives extend market exclusivity period product beyond patent term us eu japan china canada also provide minimum period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy data protection regions china however questionable whether data protection laws enforceable certain markets patent protection forms market exclusivity may expired data protection particular importance however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration regulatory data exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator specific aspects law governing market exclusivity data protection pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant sales united states us key products protected patents varying terms depending type patent filing date significant portion products patent life however lost time takes innovative company develop obtain regulatory approval new drug compensation least part lost patent term innovator may depending number factors extend expiration date one patent maximum term five years provided extension cause patent effect years date drug approval company seeking market innovative pharmaceutical us must submit complete set safety efficacy data fda innovative pharmaceutical chemical company files new drug application nda medicine biological product biologics license application bla filed type application filed affects regulatory exclusivity rights chemical products competitor seeking launch generic substitute chemical innovative drug us must file abbreviated nda anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer time time andas including paragraph iv certifications filed respect certain products evaluate andas casebycase basis warranted file suit generic manufacturer protect patent rights addition benefiting patent protection certain innovative pharmaceutical products receive periods regulatory exclusivity nda designated orphan drug receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use company may also earn six months additional exclusivity drug specific clinical trials conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity medicines approved nda also receive several types regulatory data protection innovative chemical pharmaceutical entitled five years regulatory data protection us competitors file fda approval generic substitutes innovators patent challenged described generic manufacturer may file anda fourth year fiveyear data protection period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation drug new indication basis new clinical trials receives three years data protection formulation indication biologic products us healthcare legislation enacted created approval pathway biosimilar versions innovative biological products previously exist prior time innovative biologics essentially unlimited regulatory exclusivity new regulatory mechanism fda approve products similar generic copies innovative biologics basis less extensive data required full bla innovator marketed product four years manufacturer may file application approval biosimilar version innovator product however although application approval biosimilar may filed four years approval innovator product qualified innovative biological products receive years regulatory exclusivity meaning fda may approve biosimilar version years innovative biological product first approved fda law also provides mechanism innovators enforce patents protect innovative biological products biosimilar applicants challenge patents patent litigation may begin early four years innovative biological products first approved fda us increased likelihood generic biosimilar challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products second statutory regulatory provisions us limit ability innovator company prevent generic biosimilar drugs approved launched patent litigation ongoing result developments possible predict length market exclusivity particular product certainty based solely expiration relevant patents current forms regulatory exclusivity european union patents pharmaceutical products generally enforceable eu us may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis primary route use obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation european commission ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states obtaining marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu countries process take place simultaneously product marketed eu countries process must completed company market new product pricing reimbursement procedure take months sometimes years complete throughout eu products marketing authorizations filed octobernovember subject regime eight years innovator received first community authorization medicinal product generic company may file marketing authorization application product health authorities marketing authorization application approved generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible extension years available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments products filed prior octobernovember year period data protection centralized procedures period either six years mutual recognition procedure depending member state contrast us patents eu listed regulatory authorities generic versions pharmaceutical products approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property data protection addition relevant legislation annexes related biologic medicinal products ema issued guidelines outline additional information provided biosimilar products also known generic biologics order review application marketing approval japan japan medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity china china medicines new chemical entities generally afforded six years data exclusivity approved indications dosage uncertainty chinas exclusivity laws resulted generic competition china market generic copies receive regulatory approval data exclusivity patent expirations currently unlike us china patent term restoration compensate patent term lost regulatory process general chinese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity canada canada medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations currently unlike us canada patent term restoration compensate patent term lost regulatory review process canada biologics generally treated chemicallysynthesized products respect patent rights regulatory exclusivity health canada issued draft guidance outlines additional information provided subsequent entry biologics also known biosimilar products generic biologics order review application marketing approval rest world countries outside us eu japan china canada wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eu eg switzerland among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply world trade organization wto commitments taken steps implement laws meaningful way enforcement wto actions long process governments assurance outcome thus assessing likely future market exclusivity innovative drugs developing countries take account formal legal rights political factors well marketing distribution customers promote appropriate use products directly healthcare professionals providers doctors nurse practitioners physician assistants pharmacists technologists hospitals pharmacy benefit managers pbms managed care organizations mcos also provide information appropriate use products consumers us directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceuticals see government regulation price constraints field sales medical organizations explain risks benefits approved uses products medical professionals work gain access products formularies reimbursement plans lists recommended approved medicines products including medicare part plans providing information clinical profiles products marketing sales prescription pharmaceuticals limited approved uses particular product continue develop scientific data information products provide information response unsolicited inquiries doctors medical professionals managed care organizations operations include several marketing sales organizations product marketing organization supported sales force may responsible selling one products also marketing organizations focus certain classes customers managed care entities certain types marketing tools digital consumer communications sales forces focus communicating information new products new uses well established products promotion physicians increasingly targeted physician specialists treat patients need medicines products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross sales three largest pharmaceutical wholesalers us percentage global gross sales follows mckesson corporation cardinal health inc amerisourcebergen corporation us business inventory management agreements imas substantially direct wholesaler distributor customers allow us monitor us wholesaler inventory levels requires wholesalers maintain inventory levels one month demand imas three largest wholesalers expire march imas expire december subject certain termination provisions reached agreements principal three largest wholesalers subject negotiation execution final agreements would extend termination dates imas december subject certain termination provisions number defined markets outside us established full scale distributor model make medically necessary drugs available patients continue marketing authorization trademarks products contracted services fullservice distributor provide distribution logistics regulatory pharmacovigilance sales advertising promotion certain products contracts clearly define terms conditions along services provide supply firm order period monitor inmarket sales forecasts ensure reasonable inventory levels products sale maintained fully continuously meet demand products within distributors territory responsibility sales distributorbased markets represented less companys net sales competition markets compete generally broad based highly competitive compete worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated costeffectiveness marketing effectiveness product labeling customer service research development new products processes sales products impacted new studies indicate competitors product safer effective treating disease particular form disease one products sales also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages products subject progressive price reductions decreased volume sales generic competition one biggest competitive challenges face generic pharmaceutical manufacturers us eu regulatory approval process exempts generics costly timeconsuming clinical trials demonstrate safety efficacy allowing generic manufacturers rely safety efficacy innovator product result generic pharmaceutical manufacturers typically invest far less research development researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product upon expiration loss market exclusivity product lose major portion sales product short period time rate sales decline product expiration exclusivity varies country general decline us market rapid developed countries though observed rapid declines number eu countries well also declines developed countries tend rapid developing countries rate sales decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed key primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture certain countries outside us patent protection weak nonexistent must compete generic versions shortly launch innovative products addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation information market exclusivity see intellectual property product exclusivity believe longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical needs together ability manufacture products efficiently market effectively highly competitive environment managed care organizations growth mcos us also major factor healthcare marketplace half us population participates version managed care mcos include medical insurance companies medical plan administrators healthmaintenance organizations medicare part prescription drug plans alliances hospitals physicians physician organizations organizations consolidating fewer larger entities thus enhancing purchasing strength importance us successfully compete business mcos must often demonstrate products offer medical benefits also cost advantages compared forms care new products introduce compete products already market products later developed competitors noted generic drugs exempt costly timeconsuming clinical trials demonstrate safety efficacy often lower costs brandname drugs mcos focus primarily immediate cost drugs often favor generics reason many governments also encourage use generics alternatives brandname drugs healthcare programs laws us generally allow many cases require pharmacists substitute generic drugs rated government procedures essentially equivalent brandname drug substitution must made unless prescribing physician expressly forbids exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price generally although universally successful major products included mco formularies government regulation price constraints pharmaceutical industry subject extensive global regulation regional country state local agencies federal food drug cosmetic act fdc act federal statutes regulations various state statutes regulations laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition operations subject complex federal state local foreign environmental occupational safety laws regulations anticipate laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense well significant capital investments particular importance fda us jurisdiction virtually activities imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance products many cases fda requirements increased amount time money necessary develop new products bring market us fda mandates drugs manufactured packaged labeled conformity current good manufacturing practices cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production recordkeeping quality control ensure products meet applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects us possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy occur following approval federal government extensive enforcement powers activities pharmaceutical manufacturers including authority withdraw product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed us could materially adversely affect business financial condition results operations cash flows marketing authorization products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject prescription drug marketing act pdma part fdc act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples product diversions fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda authority require companies conduct postmarketing safety studies drugs impose certain drug labeling changes relating safety mandate risk mitigation measures education healthcare providers restricted distribution medicines require companies publicly disclose data clinical trials prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state healthcare laws used protect integrity government healthcare programs office inspector general us department health human services oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal antikickback statute criminalizes offering something value induce recommendation order purchase products services reimbursed government healthcare program oig issued series guidances segments healthcare industry including compliance program guidance pharmaceutical manufacturers oig guidance includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices subscribe phrma code implemented compliance program address requirements set forth oig guidance compliance healthcare laws failure comply healthcare laws could subject us administrative legal proceedings including actions federal state government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect business financial condition results operations cash flows also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us also licensed us drug enforcement agency procure produce controlled substances therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing products regulatory requirements vary country country whether fda approval approval ema obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country many markets outside us operate environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts methods cost control eu countries example government regulates pricing new product launch often direct price controls international price comparisons controlling profits andor reference pricing markets uk germany government set pricing restrictions launch pricing freedom subsequently limited operation profit price control plan uk operation reference price system germany companies also face significant delays market access new products mainly france spain italy belgium two years elapse new medicines become available national markets additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals recent years italy example imposed mandatory price decreases existence price differentials within eu due different national pricing reimbursement laws leads significant parallel trade flows us healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact net sales participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities also participate government programs specify discounts certain government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases march us government enacted healthcare reform legislation signing law patient protection affordable care act hr reconciliation bill containing package changes healthcare bill legislation makes extensive changes current system healthcare insurance benefits intended broaden coverage reduce costs bills significantly change americans receive healthcare coverage pay also significant impact companies particular companies pharmaceutical industry healthcare related industries including bms experienced continue experience additional financial costs certain changes business new healthcare law implemented example minimum rebates medicaid drug sales increased percent percent medicaid rebates also extended drugs used riskbased medicaid managed care plans addition extend discounts certain critical access hospitals cancer hospitals covered entities required expansion b drug pricing program public health service act also required provide percent discount brandname drugs patients fall within medicare part coverage gap also referred donut hole pay annual nontaxdeductible fee federal government based allocation market share branded prior year sales certain government programs including medicare medicaid department veterans affairs department defense tricare discussion rebates programs see item managements discussion analysis financial condition results operationsnet sales critical accounting policies sources availability raw materials general purchase raw materials supplies required production products open market products purchase raw materials supplies one source source available us single source approved source among many available us thereby requiring us obtain raw materials supplies particular source attempt possible mitigate raw material supply risks inventory management alternative sourcing strategies discussion sourcing see manufacturing quality assurance discussions particular products manufacturing quality assurance meet expected product demand operate manage manufacturing network including thirdparty contract manufacturers inventory related thereto manner permits us improve efficiency maintaining flexibility reallocate manufacturing capacity pharmaceutical production processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital expenditures well regulatory approvals maintain operate flexible manufacturing network consisting internal external resources minimize unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact manufacturing see government regulation price constraints pharmaceutical manufacturing facilities located us puerto rico france italy ireland japan mexico china require significant ongoing capital investment maintenance compliance increasing regulatory requirements addition product line changes next several years expect continue modification existing manufacturing network meet complex processing standards may required newly introduced products including biologics biologics manufacturing involves complex processes traditional pharmaceutical operations fda approved large scale multiproduct bulk biologics manufacturing facility devens massachusetts may rely third parties manufacture supply us certain active ingredients necessary us manufacture various products including plavix baraclude avalide reyataz abilify erbitux sustiva franchise orencia yervoy onglyza kombiglyze forxiga maintain stable supply products take variety actions including inventory management maintenance additional quantities materials possible designed provide reasonable level ingredients held thirdparty supplier us manufacturing operations interrupted additional protection cases take steps maintain approved backup source available example rely capacity devens massachusetts facility capacity available thirdparty contract manufacturers manufacture orencia thirdparty manufacturer rely existing future products unable maintain stable supply products operate sufficient capacity meet order requirements comply government regulations manufacturing pharmaceuticals meet complex processing requirements biologics business performance prospects could negatively impacted additionally thirdparty suppliers experience extended plant shutdowns substantial unplanned increases demand suspension manufacturing regulatory reasons could experience interruption supply certain products product shortages production could resumed expanded connection divestitures licensing arrangements distribution agreements certain products certain circumstances entered agreements agreed supply products third parties addition liabilities could arise failure supply products agreements arrangements could require us invest facilities production nonstrategic products result additional regulatory filings obligations cause interruption manufacturing products success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts operations including research development purchasing facilities planning manufacturing distribution maintain qualityassurance procedures relating quality integrity technical information production processes control production processes involves detailed specifications ingredients equipment facilities manufacturing methods processes packaging materials labeling perform tests various stages production processes final product ensure product meets regulatory requirements standards tests may involve chemical physical chemical analyses microbiological testing combination along analyses quality control provided business unitsite quality assurance groups monitor existing manufacturing procedures systems used us subsidiaries thirdparty suppliers environmental regulation facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many operations permits subject modification renewal revocation issuing authorities environment health safety group monitors operations around world providing us overview regulatory requirements overseeing implementation standards compliance also incur operating capital costs matters ongoing basis expended approximately million million million capital projects undertaken specifically meet environmental requirements although believe substantial compliance applicable environmental health safety requirements permits required operations nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many current former facilities operation many years time operators facilities generated used stored disposed substances wastes considered hazardous federal state andor foreign environmental laws including us comprehensive environmental response compensation liability act cercla result soil groundwater certain facilities may contaminated may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently involved investigation remediation current former facilities also identified potentially responsible party prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites bear remediation responsibility pursuant contractual obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters see item financial statementsnote legal proceedings contingencies employees december employed approximately people foreign operations significant operations outside us conducted subsidiaries distributors geographic breakdown net sales see table captioned geographic areas item financial statementsnote business segment information discussion net sales geographic area see item managements discussion analysis financial condition results operationsnet sales international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit products limitations foreign participation local enterprises restrictive governmental actions international businesses also subject governmentimposed constraints including laws pricing reimbursement use products depending direction change relative us dollar foreign currency values increase decrease reported dollar value net assets results operations change foreign exchange rates net unfavorable impact growth rate revenues predict certainty future changes foreign exchange rates effect growth rate revenues attempt mitigate impact operational means using various financial instruments see discussions item quantitative qualitative disclosures market risk item financial statementsnote financial instruments bristolmyers squibb website internet website address wwwbmscom website make available free charge annual quarterly current reports including amendments reports soon reasonably practicable electronically file material furnishes material us securities exchange commission sec information relating corporate governance bristolmyers squibb including standards business conduct ethics code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning executive committee board directors including board committees committee charters transactions bristolmyers squibb securities directors executive officers available website investorscorporate governance caption print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly website information relating stockholder services including dividend reinvestment plan direct deposit dividends available website investorsstockholder services caption incorporate reference certain information parts proxy statement annual meeting stockholders sec allows us disclose important information referring manner please refer information proxy statement annual meeting stockholders annual report available website investorssec filings caption march item risk factors factors described could significantly negatively affect business prospects financial condition operating results credit ratings could cause trading price common stock decline additional risks uncertainties presently known us risks currently consider immaterial may also impair operations face intense competition biopharmaceutical manufacturers including innovative medicines lowerpriced generic products competition including lowerpriced generic versions products major challenge within us internationally face patent expirations increasingly aggressive generic competition competition may include new products developed competitors lower prices real perceived superior efficacy benefit safety risk profiles otherwise competitive products ii technological advances patents attained competitors iii earlierthanexpected competition generic companies iv clinical study results products competitors products v business combinations among competitors major customers vi competing interests external partnerships develop bring new products markets could also experience limited market access real perceived differences value propositions products compared competitors possible may lose market exclusivity product earlier expected pharmaceutical biotechnology industries majority innovative products commercial value usually realized period market exclusivity us countries market exclusivity expires generic versions product approved marketed usually substantial rapid declines products sales market exclusivity products based upon patent rights andor certain regulatory forms exclusivity scope patent rights vary country country may also dependent availability meaningful legal remedies country failure obtain patent intellectual property rights limitations use loss rights could material us countries including certain eu member states basic patent protection products may exist certain countries historically offer right obtain specific types patents andor licensors file markets addition patent environment outside us unpredictable validity enforceability patents predicted certainty absent relevant patent protection product data exclusivity period expires generic versions product approved marketed addition prior expiration data exclusivity competitor could seek regulatory approval submitting clinical trial data obtain marketing approval manufacturers generic products also increasingly seeking challenge patents expire key patents covering three key products atripla baraclude sprycel currently subject patent litigation cases generic manufacturers may choose launch generic product risk expiration applicable patents andor final resolution related patent litigation example may face generic competition baraclude beginning following federal courts decision invalidate composition matter patent february assurance particular product enjoy market exclusivity full period time appears estimates disclosed increased pricing pressure restrictions us abroad managed care organizations institutional purchasers government agencies programs could negatively affect net sales profit margins pharmaceutical products continue subject increasing price pressures restrictions us eu regions around world including limited rules practices managed care organizations institutional governmental purchasers ii judicial decisions governmental laws regulations medicare medicaid us healthcare reform including patient protection affordable care act potential additional us healthcare reform measures iii potential impact importation restrictions legislative andor regulatory changes pharmaceutical reimbursement medicare part formularies product pricing general iv delays gaining reimbursement andor reductions reimbursement amounts countries governmentmandated costcontainment programs v government price erosion mechanisms across europe resulting deflation pharmaceutical product pricing vi developments technology andor industry practices could directly indirectly impact reimbursement policies practices thirdparty payers vii limited market access due real perceived differences value propositions products compared competing products may experience difficulties delays development commercialization new products developing commercializing new products includes inherent risks uncertainties compounds products may appear promising development fail reach market within expected optimal timeframe fail ever reach market approved product extensions additional indications including efficacy safety concerns delay denial necessary regulatory approvals delays difficulties producing products commercial scale level excessive costs manufacture products ii failure enter successfully implement optimal alliances development andor commercialization new products iii failure maintain consistent scope variety promising latestage products iv failure one products achieve maintain commercial viability v changes regulatory approval processes may cause delays denials new product approvals observed recent trend us food drug administration delay approval decision new product beyond announced action date much six months longer regulatory approval delays especially common product expected risk evaluation mitigation strategy required fda address significant riskbenefit issues inability bring product market significant delay expected approval related launch date new product could potentially negative impact net sales earnings product acquired could result significant impairment process research development intangible assets certain acquired pipeline programs cancelled believe commercial prospects reduced may recognize material noncash impairment charges programs noncash impairment charge could material billion impairment bms recorded finally natural manmade disaster sabotage research development labs compound library andor loss key molecules intermediaries could negatively impact product development cycle failure execute business strategy could adversely impact growth profitability biopharmaceutical company focus innovative products high unmet medical needs build foundation future strategy grow key marketed products advance latestage pipeline manage costs may able consistently replenish innovative pipeline internal research development transactions third parties competition among major pharmaceutical companies acquisition product licensing opportunities intense may able locate suitable acquisition targets licensing partners reasonable prices successfully execute transactions also may able realize expected increased efficiencies effectiveness continuous improvement initiatives changes structure operations including recent reorganization commercial operations creation enterprises services organization addition realizing synergies expected benefits acquisitions divestitures mergers alliances restructurings strategic initiatives may take longer expected complete may encounter difficulties including need regulatory approval applicable unable support grow currently marketed products successfully execute launches newly approved products advance latestage pipeline manage costs effectively could experience significant material negative impact operating results financial condition addition failure hire retain personnel right expertise experience critical operations could adversely impact execution business strategy businesses acquire may underperform may able successfully integrate existing business may continue support pipeline licensing acquisitions strategy august acquired amylin pharmaceuticals inc amylin biopharmaceuticals company dedicated discovery development commercialization innovative medicines patients diabetes metabolic diseases amylin acquired businesses products technologies may underperform relative expectations may negatively impact financial results including potential impairment charges acquired intangible assets including identifiable intangible assets attributed amylin acquisition billion acquisition date future sales profits cash flows acquired companys products technologies pipeline candidates may materialize due lower product uptake delayed missed pipeline opportunities inability capture expected synergies increased competition safety concerns regulatory issues supply chain problems factors beyond control substantial difficulties costs delays could result integrating acquisitions including research development manufacturing distribution sales marketing promotion information technology activities ii policies procedures processes controls compliance iii company cultures iv compensation structures human resource activities v tax considerations depend certain key products net sales cash flows earnings historically derived majority revenue earnings key products example plavix represented revenues becoming less dependent single product still derive significant amount revenues key products abilify net sales billion represented revenues reyataz sustiva franchise combined net sales billion represented approximately revenues baraclude sprycel orencia net sales exceeded billion reduction net sales one products could significantly negatively impact net sales cash flows earnings changes us foreign laws regulations may negatively affect net sales profit margins could become subject new government laws regulations additional healthcare reform initiatives us countries including additional mandatory discounts ii changes corporate tax regulation including part proposed us budget deficit reduction package could include limiting foreign tax credits taxing certain tax havens taxing certain excess income transferring intellectual property limiting disallowing certain us deductions operating interest expenses changing rules earnings repatriations eliminating certain tax credits well changing tax rate phasing currently available tax benefits us certain foreign countries changes tax law iii new laws regulations judicial governmental decisions affecting pricing drug reimbursement receivable repayment access marketing within across jurisdictions iv changes intellectual property law v changes accounting standards vi increasing data privacy regulations enforcement vii emerging new requirements regarding payments healthcare professionals viii matters compulsory licenses could alter protections afforded one products legal regulatory changes could negatively affect business operating results financial condition company emerging legislation reduce budget deficit us countries enacted likely reduce operating results product labeling changes marketed products could potentially result unexpected safety efficacy concerns negative impact products sales regulatory authorities change labeling pharmaceutical product time including product market years changes often result additional data postmarketing studies headtohead trials reporting adverse events studies identify biomarkers objective characteristics indicate particular response product therapy studies produce important additional information product new information added products label affect safety andor efficacy profile product leading product recalls withdrawals declining revenue well product liability claims sometimes additional information studies identifies portion patient population may nonresponsive medicine labeling changes based studies may limit patient population changes labeling plavix erbitux years ago studies providing additional information may sponsored us also sponsored competitors insurance companies government institutions managed care organizations influential scientists investigators interested parties additional safety efficacy information studies assist us healthcare providers identifying best patient population products also negative impact sales product extent patient population product labeling becomes limited additionally certain study results especially headtohead trials could affect products formulary listing could also adversely affect sales could experience difficulties delays manufacturing distribution sale products product supply related patient access products could negatively impacted among things seizure recalls products forced closings manufacturing plants ii supply chain continuity including natural manmade disasters one facilities critical supplier vendor well failure failure vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing iii manufacturing quality assurancequality control supply problems governmental approval delays iv failure sole source single source supplier provide us necessary raw materials supplies finished goods extended period time v failure thirdparty manufacturer supply us finished product time vi construction regulatory approval delays related new facilities expansion existing facilities including intended support future demand biologics products vii failure meet new emerging regulations requiring products tracked throughout distribution channels using unique identifiers viii manufacturing distribution issues including limits manufacturing capacity due regulatory requirements changes types products produced biologics physical limitations business interruptions adverse outcomes legal matters could negatively affect business current future lawsuits claims proceedings government investigations could preclude delay commercialization products could potentially adversely affect operations profitability liquidity financial condition possible insurance recoveries available legal matters include intellectual property disputes ii sales marketing practices us internationally iii adverse decisions litigation including product liability commercial cases iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers vi product pricing promotional matters vii lawsuits claims asserting investigations violations securities antitrust federal state pricing consumer protection antibribery us foreign corrupt practice act uk antibribery act laws viii environmental health safety matters ix tax liabilities depend third parties meet contractual regulatory obligations rely suppliers vendors outsourcing partners alliance partners third parties research develop manufacture commercialize copromote sell products manage certain human resource finance information technology functional services meet contractual regulatory obligations relation arrangements us thirdparty providers located markets subject political risk corruption infrastructure problems natural disasters addition country specific privacy data security risks given current legal regulatory environments failure critical third party meet obligations adequately deploy business continuity plans event crisis andor satisfactorily resolve significant disagreements us address factors could material adverse impact companys operations results addition third parties violate alleged violated laws regulations including us foreign corrupt practice act uk bribery act similar laws regulations performance obligations us possible could suffer financial reputational harm negative outcomes including possible legal consequences increasingly dependent information technology systems infrastructure face certain risks including cyber security data leakage significant breakdown invasion corruption destruction interruption critical information technology systems infrastructure employees others authorized access systems unauthorized persons could negatively impact operations everincreasing use evolution technology including cloudbased computing creates opportunities data leakage confidential information could also experience business interruption information theft reputational damage malware cyber attacks may compromise system infrastructure lead data leakage either internally thirdparty providers although aggregate impact operations financial condition material date targets events nature expect continue invested industry appropriate protections monitoring practices data information technology reduce risks continue monitor systems ongoing basis current potential threats assurance however efforts prevent breakdowns breaches third party providers databases systems could adversely affect business expansion social media platforms presents new risks challenges inappropriate andor unauthorized use certain media vehicles could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information addition negative inaccurate posts comments us social networking web site could damage reputation brand image goodwill disclosure nonpublic company sensitive information external media channels could lead information loss might structured processes place secure protect information identifying new points entry social media continues expand presents new challenges adverse changes us global regional local economic conditions could adversely affect profitability worlds major economies hold historicallyhigh debt levels experiencing slow economic growth high unemployment european sovereign debt crisis strained government spending created capital markets volatility significant operations europe including manufacturing exposure customer credit risks europe including governmentguaranteed hospital receivables likely increase ability factor receivables becomes limited addition future pension plan funding requirements continue sensitive global economic conditions related impact equity markets also exposed commercial risks economic factors control could pose significant challenges underlying profitability changes foreign currency exchange rates interest rates could material adverse effect operating results liquidity significant operations outside us net sales operations outside us accounted approximately net sales exposed fluctuations foreign currency exchange rates difficult mitigate also exposed changes interest rates ability access money markets andor capital markets could impeded adverse liquidity market conditions occur illegal distribution sale third parties counterfeit versions products stolen products could negative impact reputation business third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards patient receives counterfeit drug may risk number dangerous health consequences reputation business could suffer harm result counterfeit drugs sold brand name addition thefts inventory warehouses plants intransit properly stored sold unauthorized channels could adversely impact patient safety reputation business item b unresolved staff comments none item properties world headquarters located park avenue new york ny lease approximately square feet floor space lease approximately properties countries manufacture products worldwide locations owned us manufacturing locations aggregate square feet floor space geographic area follows december number locations square feet united states europe rest world total portions manufacturing locations properties owned leased us us elsewhere used research development administration storage distribution information properties see item businessmanufacturing quality assurance item legal proceedings information pertaining legal proceedings found item financial statementsnote legal proceedings contingencies incorporated reference herein item mine safety disclosures applicable part ia executive officers registrant listed information executive officers february executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve pleasure board directors name current position age employment history past years lamberto andreotti executive vice president president worldwide pharmaceuticals chief executive officer director division company member senior management team executive vice president chief operating officer worldwide pharmaceuticals division company executive vice president chief operating officer president chief operating officer director company present chief executive officer director company charles bancroft vice president finance worldwide pharmaceuticals division executive vice president chief financial officer company member senior management team chief financial officer company present executive vice president chief financial officer company giovanni caforio md senior vice president us oncology worldwide pharmaceuticals president us pharmaceuticals division company member senior management team senior vice president oncology global commercialization senior vice president oncology immunoscience global commercialization present president us pharmaceuticals joseph c caldarella vice president corporate controller senior vice president corporate controller present senior vice president corporate controller beatrice cazala president emea worldwide medicines international executive vice president commercial operations president emea asia pacific worldwide medicines international member senior management team president global commercialization president europe senior vice president commercial operations president global commercialization europe emerging markets present executive vice president commercial operations francis cuss mb bchir frcp senior vice president discovery exploratory clinical research senior vice president research present senior vice president research research development member senior management team brian daniels md senior vice president global clinical development research senior vice president global development development division company medical affairs research development present senior vice president global development medical affairs member senior management team research development john e elicker senior director investor relations senior vice president public affairs investor vice president investor relations relations senior vice president investor relations member senior management team present senior vice president public affairs investor relations frances heller head strategic alliances novartis pharmaceuticals senior vice president business development executive vice president exelixis member senior management team instructor stanford university present senior vice president business development sandra leung vice president corporate secretary acting general counsel general counsel corporate secretary present general counsel corporate secretary member senior management team samuel j moed senior vice president worldwide strategy operations senior vice president strategic planning analysis senior vice president strategy member senior management team present senior vice president strategic planning analysis louis schmukler senior vice president pharmaceutical operating unit wyeth president global manufacturing supply senior vice president specialtybiotechnology operating unit pfizer member senior management team present president global manufacturing supply elliott sigal md phd executive vice president chief scientific officer president research executive vice president chief scientific officer development president research development director present executive vice president chief scientific officer president member senior management team research development director company paul von autenried vice president chief information officer senior vice president enterprise services chief senior vice president chief information officer information officer present senior vice president enterprise services chief information member senior management team officer part ii item market registrants common stock stockholder matters market prices bristolmyers squibb common preferred stocks traded new york stock exchange nyse symbol bmy quarterly summary high low market prices presented high low high low common first quarter second quarter third quarter fourth quarter preferred first quarter second quarter third quarter fourth quarter first third fourth quarters observable trades companys preferred stock holders common stock number record holders common stock december number record holders based upon actual number holders registered books date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies dividends board directors declared following dividends per share paid quarters indicated common preferred first quarter second quarter third quarter fourth quarter december board directors declared quarterly dividend per share common stock paid february shareholders record january board directors also declared quarterly dividend per share preferred stock payable march shareholders record february issuer purchases equity securities following table summarizes surrenders repurchases equity securities month period ended december total number shares purchased part publicly approximate dollar value average price announced shares may yet total number paid plans purchased period shares purchaseda per sharea programsb plans programsb dollars millions except per share data january february march three months ended march april may june three months ended june july august september three months ended september october november december three months ended december twelve months ended december total number shares purchased total number shares purchased part publicly announced programs different shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations b may board directors authorized repurchase billion common stock june board directors increased authorization repurchase common stock additional billion repurchase program expiration date may suspended discontinued time item selected financial data five year financial summary amounts millions except per share data income statement dataa net sales continuing operations net earnings net earnings attributable noncontrolling interest bms net earnings per common share attributable bms basic diluted average common shares outstanding basic diluted cash dividends paid bms common preferred stock cash dividends declared per common share financial position data december cash cash equivalents marketable securitiesb total assets longterm debtc equity discussion items affected comparability results years see item managements discussion analysis financial condition results operationsnon gaap financial measures b marketable securities include current noncurrent assets c also includes current portion longterm debt item managements discussion analysis financial condition results operations executive summary bristolmyers squibb company may referred bristolmyers squibb bms company us global biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases license manufacture market distribute sell pharmaceutical products global basis following key events transactions occurred discussed detail strategy product pipeline developments results operations sections managements discussion analysis net sales earnings declined result loss exclusivity plavix clopidogrel bisulfate avaproavalide irbesartanirbesartan hydrochlorothiazide received significant regulatory approvals pertaining eliquis apixaban stroke prevention patients nonvalvular atrial fibrillation nvaf forxiga dapagliflozin orencia abatacept subcutaneous formulation acquired amylin pharmaceuticals inc amylin expanded diabetes alliance arrangement astrazeneca plc astrazeneca include amylinrelated products discontinued development bms formerly inx compound acquired part acquisition inhibitex inc inhibitex treat hepatitis c virus infection interest patient safety resulted billion pretax impairment charge highlights following table summary financial highlights year ended december dollars millions except per share data net sales total expenses earnings income taxes provision forbenefit income taxes effective taxbenefit rate net earnings attributable bms gaap nongaap diluted earnings per share gaap nongaap cash cash equivalents marketable securities nongaap financial measures including nongaap earnings related eps information adjusted exclude specified items represent certain costs expenses gains losses items impacting comparability financial results detailed listing specified items information reconciliations nongaap financial measures see nongaap financial measures business environment pharmaceuticalbiotechnology industry highly competitive subject numerous government regulations many competitive factors may significantly affect sales products including product efficacy safety price demand competition costeffectiveness marketing effectiveness market access product labeling quality control quality assurance manufacturing operations research development new products successfully compete healthcare industry must demonstrate products offer medical benefits cost advantages new product introductions often compete products already market therapeutic category addition potential competition new products competitors may introduce future manufacture branded products priced higher generic products generic competition one leading challenges pharmaceuticalbiotechnology industry majority innovative products commercial value usually realized market exclusivity period afterwards longer protected patent subject new competing products form generic brands upon exclusivity loss experience significant reduction products sales short period time competitors seeking approval biological products full biologics license application bla must file safety efficacy data address challenges biologics manufacturing involving complex processes costs pharmaceutical operations us healthcare legislation enacted abbreviated path regulatory approval generic versions biological products path approval biosimilar products us healthcare legislation significantly affects regulatory data exclusivity biological products legislation provides regulatory mechanism allowing regulatory approval biologic drugs similar generic copies innovative drugs basis less extensive data required full bla possible time reasonably assess impact us biosimilar legislation company globally healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact net sales march us government enacted healthcare reform legislation signing law patient protection affordable care act hr reconciliation bill containing package changes healthcare bill continue experience additional financial costs certain changes business healthcare law provisions become effective aggregate financial impact us healthcare reform next years depends number factors including limited pending implementation guidance potential changes sales volume eligible new rebates discounts fees impact cost sharing arrangements certain alliance partners future net sales beginning could potentially positively impacted expected increase number people healthcare coverage patient protection affordable care act many markets outside us operate environments governmentmandated costcontainment programs regulatory bodies groups exerting downward pressure pricing example pricing freedom limited uk operation profit control plan germany operation reference price system many european countries continuing fiscal challenges healthcare payers including government agencies reduced expected continue reduce cost healthcare actions directly indirectly impose additional price restrictions companies also face significant delays market access new products two years elapse drug approval new medicines available countries growth managed care organizations mcos us significantly impacted competition healthcare industry mcos seek reduce healthcare expenditures participants volume purchases longterm contractual discounts various pharmaceutical providers market potential created large pool participants marketing prescription drugs mcos important part strategy companies compete inclusion mco formularies generally successful key products included believe developments managed care industry including continued consolidation continue downward pressure prices pharmaceutical biotechnology production processes complex highly regulated vary widely product shifting adding manufacturing capacity usually lengthy process requiring significant capital expenditures regulatory approvals biologics manufacturing involves complex processes traditional pharmaceutical operations biologics become larger percentage product portfolio continue maintain supply arrangements thirdparty manufacturers incur substantial investments increase internal capacity produce biologics commercial scale fda approved large scale multiproduct bulk biologics manufacturing facility devens massachusetts may maintain competitive position market strive uphold position depending success discovering developing delivering innovative costeffective products help patients prevail serious diseases subject number significant pending lawsuits claims proceedings investigations possible time reasonably assess final outcomes investigations litigations additional discussion legal matters see item financial statementsnote legal proceedings contingencies strategy past years transformed company focused biopharmaceutical company continue focus sustaining business building foundation future growing newer key marketed products advancing pipeline portfolio managing costs expect portfolio become increasingly diversified across products geographies next years experienced substantial exclusivity losses year plavix avaproavalide together billion net sales preparing number years expected experienced rapid precipitous material decline plavix avaproavalide net sales reduction net income operating cash flow events norm industry companies experience loss exclusivity significant product also face additional exclusivity losses coming years also face significant challenges increasingly complex global regulatory environment global economic uncertainty particularly european union eu believe strategy grow newer marketed products robust research development rd pipeline particularly within therapeutic areas immunooncology cardiovascularmetabolic disease virology position us well future continue expand biologics capabilities still rely significantly small molecules strongest reliable starting point discovering potential new medicines large molecules biologics derived recombinant dna technologies becoming increasingly important currently pipeline compounds biologics four key marketed products including yervoy ipilimumab also continue support pipeline licensing acquisitions strategy referred string pearls third quarter acquired amylin biopharmaceutical company dedicated discovery development commercialization innovative medicines patients diabetes metabolic diseases following completion acquisition amylin entered collaboration astrazeneca pharmaceuticals lp wholly owned subsidiary astrazeneca builds upon existing alliance expanding collaboration strategy currently integrating amylin business development manufacturing commercial operations also seeking build relationships academic organizations innovative programs capabilities complement internal efforts product pipeline developments manage research development rd programs portfolio basis investing resources stage research development early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth consider rd programs entered phase iii development significant programs constitute latestage development pipeline phase iii development programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations spending programs represents approximately annual rd expenses individual investigational compound marketed product represented rd expenses last three years expect latestage development programs make market latestage development programs rd programs could potentially impact revenue earnings within next years following recent significant developments marketed products latestage pipeline eliquis oral factor xa inhibitor targeted stroke prevention nvaf prevention treatment venous thromboembolic vte disorders eliquis part strategic alliance pfizer inc pfizer december us food drug administration fda approved eliquis reduce risk stroke systemic embolism patients nvaf eliquis also received regulatory approval indication japan canada december eu november south korea january december company announced results phase iii amplifyext trial evaluated treatment eliquis compared placebo one year period prevention recurrent vte patients already completed six months anticoagulation treatment vte including deep vein thrombosis pulmonary embolism trial extended treatment eliquis mg mg twice daily demonstrated superiority versus placebo reduction composite endpoint symptomatic recurrent vte death cause eliquis also superior placebo predefined secondary efficacy outcome recurrent vte vterelated death rate primary safety outcome major bleeding comparable across treatment groups october company announced publication lancet reductions stroke systemic embolism major bleeding mortality demonstrated eliquis compared warfarin aristotle trial consistent across wide range stroke bleeding risk scores patients nvaf march additional analyses aristotle averroes clinical trials presented american college cardiologys st annual scientific session forxiga oral sodiumglucose cotransporter sglt inhibitor treatment diabetes part alliance astrazeneca november ec approved forxiga treatment type diabetes eu june nd american diabetes association scientific sessions company astrazeneca announced results phase iii clinical study showed forxiga mg demonstrated significant reductions blood sugar levels glycosylated hemoglobin levels hbac compared placebo weeks either agent added existing sitagliptin therapy without metformin adult patients type diabetes results maintained week extension similar results observed data stratified background therapy study also demonstrated significant reductions total body weight fasting plasma glucose levels patients taking forxiga added sitigliptin without metformin results maintained throughout duration study january fda issued complete response letter crl regarding nda dapagliflozin crl requests additional clinical data allow better assessment benefitrisk profile dapagliflozin companies continue work closely fda determine appropriate next steps dapagliflozin application ongoing discussions health authorities countries part application procedures company met fda path forward potential approval forxiga us company provide additional data ongoing studies fda expects able resubmit nda forxiga mid time company expects fda sixmonth period review resubmission hold advisory committee meeting hepatitis c portfolio peginterferon lambda novel potential firstinclass type interferon development daclatasvir nsa replication complex inhibitor development asunaprevir ns protease inhibitor development november company announced results global dlite phase iib study week regimen combining investigational compound peginterferon lambdaa investigational directacting antiviral daa daclatasvir ribavirin achieved sustained virologic response weeks posttreatment treatmentnave genotype b chronic hepatitis c virus infection patients achieved protocoldefined response november company announced phase ii data demonstrating week triple daa treatment regime daclatasvir asunaprevir bms nsb nonnucleoside polymerase inhibitor achieved sustained virologic response weeks posttreatment treatment nave genotype chronic hepatitis c virus infection patients november company announced phase ii data demonstrating dual regiment daclatasvir asunaprevir without interferon ribavarin achieved high rates sustained virologic response weeks posttreatment patients genotype b hepatitis c virus infections prior null responders alfa interferon ribavarin elotuzumab antics antibody investigation treatment multiple myeloma december company announced results small randomized phase ii study patients previously treated myeloma two doses tested mgkg mgkg combination lenalidomide lowdose dexamethasone mgkg arm median progressionfree survival pfs time without disease progression death reached months follow n objective response rate orr patients received elotuzumab dose mgkg median pfs months n orr necitumumab novel targeted cancer therapy nonsmall cell lung cancer november provided notice termination global codevelopment cocommercialization arrangement necitumumab imcf fully human monoclonal antibody investigated anticancer treatment discovered imclone part alliance company eli lilly company lilly rights returning lilly termination effective may though lilly may terminate earlier sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv february company announced fda granted additional sixmonth period exclusivity market sustiva exclusivity sustiva us scheduled expire march baraclude entecavir oral antiviral agent treatment chronic hepatitis b february us district court district delaware invalidated composition matter patent covering baraclude scheduled expire october labeling update baraclude approved fda include data african americans liver transplant recipients chronic hepatitis b infection erbitux cetuximab monoclonal antibody designed exclusively target block epidermal growth factor receptor expressed surface certain cancer cells multiple tumor types well normal cells currently indicated use colorectal cancer head neck cancer erbitux part alliance lilly july fda granted full approval erbitux combination chemotherapy regimen folfiri irinotecan fluorouracil leucovorin firstline treatment patients kras mutationnegative epidermal growth factor receptorexpressing metastatic colorectal cancer determined fda approved tests use april fda issued crl regarding supplemental biologics license application sbla firstline nonsmall cell lung cancer stated based current data package firstline indication erbitux combination vinorelbine cisplatin approvable lilly company plan resubmit filing yervoy ipilimumab monoclonal antibody treatment patients unresectable inoperable metastatic melanoma november national institute health clinical excellence nice recommended yervoy approved eu treatment previously treated metastatic advanced melanoma within final appraisal determination important recommendation enable eligible patients england wales routinely access treatment yervoy national health services september company announced european society medical oncology congress longterm followup data study evaluated newlydiagnosed patients treated yervoy mgkg combination dacarbazine versus dacarbazine alone fiveyear followup data rollover study evaluated patients yervoy mgkg mgkg survival rates observed study years three four stable higher patients treated yervoy plus dacarbazine versus patients received dacarbazine alone estimated survival rates study remained unchanged relatively stable five years compared four years newlydiagnosed patients previouslydiagnosed patients orencia fusion protein indicated rheumatoid arthritis ra october ec granted marketing authorization subcutaneous formulation orencia combination methotrexate treatment moderate severe active ra adults june european league rheumatism annual european congress rheumatology company announced ample headto head trial patients comparing subcutaneous formulation orencia vs humira adalimumab background methotrexate mtx biologic nave patients moderate severe ra met primary endpoint measured noninferiority demonstrating orencia plus mtx achieved comparable rates efficacy american college rheumatology criteria percent acr response one year vs humira plus mtx may company announced fda approved companys biologics manufacturing facility devens massachusetts commercial production orencia nulojix belatacept fusion protein novel immunosuppressive activity prevention kidney transplant rejection june american transplant congress company announced new fouryear results longterm extensions lte benefit benefitext clinical trials nulojix first tcell costimulation blocker indicated prophylaxis organ rejection adult epsteinbarr virus seropositive patients receiving kidney transplant combination basiliximab induction mycophenolate mofetil corticosteroids results showed safety profile nulojix year four consistent compared results year three new safety signals identified renal function benefit versus cyclosporine maintained four years patients enrolled lte benefit benefitext trials onglyzakombiglyze saxagliptinonce daily combination saxagliptin metformin hydrochloride extendedrelease treatment type diabetes part strategic alliance astrazeneca july company astrazeneca announced th world congress heart disease results analyses showing onglyza mg demonstrated improvements across key measures blood sugar control glycosylated hemoglobin levels hbac fasting plasma glucose fpg post prandial glucose ppg compared placebo adult patients type diabetes high risk cardiovascular disease addition august company discontinued development bms decision made interest patient safety see item financial statementsnote goodwill intangible assets information results operations net sales composition changes net sales follows year ended december vs vs net sales analysis change analysis change total foreign total foreign dollars millions change volume price exchange change volume price exchange united statesa europeb rest worldc otherd na na na na total includes puerto rico b includes russia turkey c includes japan china canada australia brazil among countries includes royaltyrelated revenues sales attributed supply agreements change excess change us net sales attributed volume reflects recent exclusivity losses plavix avaproavalide partially offset increased demand key products addition byetta bydureon symlin following completion acquisition amylin million change us net sales attributed volume reflects launch yervoy increased demand several key products partially offset decreased prescription demand avaproavalide plavix change us net sales attributed price periods result higher average net selling prices plavix abilify partially offset reduction contractual share abilify net sales reduction higher rebates discounts resulting us healthcare reform legislation see key products discussion sales key product net sales europe decreased primarily due unfavorable foreign exchange lower sales certain mature brands divestitures generic competition well generic competition plavix avaproavalide partially offset sales growth key products net sales europe increased favorable foreign exchange sales growth key products offset previously mentioned lower sales certain mature brands generic competition plavix avaproavalide net sales periods negatively impacted continuing fiscal challenges many european countries healthcare payers including government agencies reduced expected continue reduce cost healthcare actions directly indirectly impose additional price reductions measures include limited mandatory discounts rebates price reductions restrictive measures net sales rest world decreased growth certain key products japan china south korea offset generic competition plavix avaproavalide timing government purchases certain countries lower sales mature brands generic competition divestitures net sales rest world increased primarily due growth certain key products japan china south korea favorable foreign exchange partially offset generic competition avaproavalide lower sales mature brands generic competition divestitures net sales increased enhanced royaltyrelated revenues higher sales attributed active pharmaceutical ingredients supply agreements resulting recent divestitures manufacturing facilities restructured alliance agreements net sales expected continue increase result higher royalties alliance revenue attributed restructured sanofi agreement new matureoverthecounter brands collaborative agreements single country outside us contributed total net sales general business seasonal information us pharmaceutical prescriber demand reference made table within estimated enduser demand sets forth comparison changes net sales estimated total prescription growth retail mail order customers certain key products us nonus net sales categorized based upon location customer revenue reduced presented net grosstonet sales adjustments described critical accounting policies reconciliation gross sales net sales significant category grosstonet sales adjustments follows year ended december change dollars millions vs vs gross sales grosstonet sales adjustments chargebacks related government programs cash discounts managed healthcare rebates contract discounts medicaid rebates sales returns adjustments total grosstonet sales adjustments net sales activities ending balances significant category grosstonet sales reserve adjustments follows healthcare chargebacks rebates related government cash contract medicaid sales dollars millions programs discounts discounts rebates returns adjustments total balance january provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation balance december provision related sales made current period provision related sales made prior periods returns payments amylin acquisition impact foreign currency translation balance december grosstonet sales adjustment rates primarily function changes sales mix contractual legislative discounts rebates grosstonet sales adjustments decreased increased due grosstonet adjustment categories sales returns adjustments decreased result lower plavix sales following loss exclusivity managed healthcare rebates contract discounts also decreased due million reduction estimated amount medicare part coverage gap discounts attributable prior period rebates receiving actual invoices nonrenewal plavix contract discounts medicare part program january rebates discounts increased due discount patients within medicare part coverage gap medicaid rebates also decreased due million reduction estimated amount managed medicaid rebates attributable prior periods receiving actual invoices medicaid rebates increased due full year impact expansion rebates drugs used risk based medicaid managed care plans higher average net selling prices plavix higher medicaid channel sales provision sales returns increased result loss exclusivity us plavix may avaproavalide march us sales return reserves products december million determined considering several factors including estimated inventory levels distribution channels accordance company policy products eligible returned six months prior months product expiration additional adjustments reserves might required future revised estimates various assumptions including actual returns generally expected occur sales returns included million reduction million us return reserve established connection recall certain lots avalide due lower returns expected adjustments increased result copay coupon programs although presented grosstonet adjustment tables contractual share abilify atripla grosstonet sales adjustments approximately billion billion billion increases primarily attributed additional rebates discounts required us healthcare reform key products net sales key products represented total net sales following table presents us international net sales key product percentage change prior period foreign exchange impact compared prior period commentary detailing reasons significant variances key products provided change attributable year ended december change foreign exchange dollars millions vs vs vs vs key products plavix clopidogrel bisulfate us nonus avaproavalide irbesartanirbesartanhydrochlorothiazide us nonus eliquis apixaban na na na na na na us na na na na nonus na na na na na na abilify aripiprazole us nonus reyataz atazanavir sulfate us nonus sustiva efavirenz franchise us nonus baraclude entecavir us nonus erbitux cetuximab us nonus sprycel dasatinib us nonus yervoy ipilimumab na na na na us na na nonus na na na na orencia abatacept us nonus nulojix belatacept na na na na us na na nonus na na na na na onglyzakombiglyze saxagliptinsaxagliptin metformin us nonus change excess change attributable year ended december change foreign exchange dollars millions vs vs vs vs key products continued byetta exenatide na na na na na na us na na na na nonus na na na na na na bydureon exenatide extendedrelease injectable suspension na na na na na na us na na na na nonus na na na na na na mature products us nonus change excess plavix platelet aggregation inhibitor part alliance sanofi us net sales decreased continue decrease due loss exclusivity may us net sales increased primarily due higher average net selling prices estimated total us prescription demand decreased international net sales continue negatively impacted generic clopidogrel products eu canada australia avaproavalide known eu aprovelkarvea angiotensin ii receptor blocker treatment hypertension diabetic nephropathy also part sanofi alliance us net sales decreased due loss exclusivity march decreased due market share losses subsequent avalide supply shortage first quarter associated previously reported recalls decrease us net sales partially offset higher average net selling prices estimated returns total estimated us prescription demand decreased international net sales decreased periods due lower demand including generic competition certain eu markets canada eliquis oral factor xa inhibitor targeted stroke prevention atrial fibrillation prevention treatment vte disorders eliquis part strategic alliance pfizer eliquis approved us prevention stroke systemic embolism adult patients nvaf december eliquis approved eu vte prevention may launched limited number eu countries beginning may eliquis also approved eu prevention stroke systemic embolism adult patients nvaf november eliquis approved december japanese ministry health labor welfare prevention ischemic stroke systemic embolism patients nvaf abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder part strategic alliance otsuka us net sales increased due higher average net selling prices million reduction bmss share estimated amount customer rebates discounts attributable based actual invoices received partially offset fluctuations retail buying patterns us net sales increased due higher overall demand higher average net selling prices us net sales periods negatively impacted reduction contractual share net sales expected continue negatively impacted result reduction bmss contractual share abilify net sales estimated approximately estimated total us prescription demand increased international net sales increased periods primarily due higher demand international net sales impacted unfavorable foreign exchange favorable foreign exchange reyataz protease inhibitor treatment human immunodeficiency virus hiv us net sales increased due higher average net selling prices estimated total prescription demand decreased increased international net sales decreased due unfavorable foreign exchange timing government purchases certain countries lower demand resulting competing products international net sales increased due higher demand sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg product sold joint venture gilead us net sales increased periods primarily due higher demand higher average net selling prices estimated total us prescription demand decreased increased international net sales decreased due unfavorable foreign exchange international net sales increased primarily due higher demand baraclude oral antiviral agent treatment chronic hepatitis b net sales periods increased primarily due higher demand may experience rapid significant decline us net sales beginning due possible generic competition following federal courts decision february invalidating composition matter patent erbitux monoclonal antibody designed exclusively target block epidermal growth factor receptor expressed surface certain cancer cells multiple tumor types well normal cells currently indicated use colorectal cancer head neck cancer erbitux part strategic alliance lilly sold us almost exclusively us net sales remained relatively flat increased primarily due higher demand sprycel oral inhibitor multiple tyrosine kinases indicated treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate firstline treatment adults philadelphia chromosomepositive chronic myeloid leukemia chronic phase sprycel part strategic alliance otsuka us net sales periods increased primarily due higher demand higher average net selling prices estimated total us prescription demand increased international net sales periods increased primarily due higher demand international net sales impacted unfavorable foreign exchange favorable foreign exchange demand positively impacted approval sprycel firstline treatment adult patients newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase us eu fourth quarter yervoy monoclonal antibody treatment patients unresectable inoperable metastatic melanoma yervoy net sales increased higher demand since launch us second quarter continued launches number international countries since second quarter orencia fusion protein indicated adult patients moderate severe rheumatoid arthritis inadequate response one currently available treatments methotrexate antitumor necrosis factor therapy us net sales increased periods primarily due higher demand including launch orencia subcutaneous formulation sc fourth quarter higher average net selling prices international net sales increased periods primarily due higher demand including launch orencia sc certain european markets beginning second quarter international net sales impacted unfavorable foreign exchange favorable foreign exchange nulojix fusion protein novel immunosuppressive activity targeted prevention kidney transplant rejection nulojix approved launched us eu onglyzakombiglyze known eu onglyzakomboglyze oncedaily oral tablet treatment type diabetes part strategic alliance astrazeneca us net sales onglyzakombiglyze increased periods primarily due higher overall demand higher average net selling prices kombiglyze launched us fourth quarter international net sales increased periods primarily due higher demand partially offset unfavorable foreign exchange byetta twice daily glucagonlike peptide glp receptor agonist treatment type diabetes byetta net sales included results following completion acquisition amylin third quarter bydureon onceweekly glp receptor agonist treatment type diabetes bydureon launched amylin us first quarter eu second quarter net sales included results following completion acquisition amylin third quarter mature products includes products including lost exclusivity major markets overthecounter brands royalty related revenue us net sales continued decrease generic erosion certain products partially offset sales symlin following completion amylin acquisition third quarter international net sales decreased periods due continued generic erosion certain brands unfavorable foreign exchange estimated us prescription change data provided throughout report includes information retail mail order channels reflect product demand within channels hospitals home health care clinics federal facilities including veterans administration hospitals longterm care among others data provided wolters kluwer health wk except sprycel based source prescription audit sprycel demand based upon information nextgeneration prescription service version national prescription audit provided ims health ims data product respective service providers recordkeeping projection processes therefore subject inherent limitations estimates based sampling may include margin error continuously seek improve quality estimates prescription change amounts ultimate patientconsumer demand reviewing calculation methodologies employed analyzing internal thirdparty data expect continue review refine methodologies processes calculation estimates monitor quality third parties data used calculations calculated estimated total us prescription change weightedaverage basis reflect fact mail order prescriptions include greater volume product supplied compared retail prescriptions mail order prescriptions typically reflect day prescription whereas retail prescriptions typically reflect day prescription calculation derived multiplying mail order prescription data factor approximates three adding retail prescriptions believe calculation estimated total us prescription change based weightedaverage approach provides superior estimate total prescription demand retail mail order channels use methodology internal demand reporting estimated enduser demand following tables set forth key products sold us years ended december change reported us net sales year ii estimated total us prescription change retail mail order channels calculated us based thirdparty data weightedaverage basis iii months inventory hand wholesale distribution channel year ended december december change us change us net sales total prescriptions months hand dollars millions plavix avaproavalide abilify reyataz sustiva franchisea baraclude erbituxb na na sprycel yervoybd na na na na orenciac na na nulojixbd na na na na onglyzakombiglyze byettae na na na na na na bydureone na na na na na na sustiva franchise includes sales sustiva well revenue bulk efavirenz included combination therapy atripla months hand relates sustiva b erbitux yervoy nulojix parenterally administered products prescriptionlevel data physicians write prescriptions products c orencia intravenous formulation parenterally administered product prescriptionlevel data physicians write prescriptions product orencia subcutaneous formulation orencia sc parenterally administered launched us fourth quarter orencia sc sales million million yervoy nulojix launched us second quarter e byetta bydureon net sales included results following completion acquisition amylin third quarter change excess pursuant us securities exchange commission sec consent order described sec consent order monitor level inventory hand us wholesaler distribution channel outside us direct customer distribution channel obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception estimated levels inventory distribution channel excess one month hand products material dates indicated us products estimated levels inventory distribution channel excess one month hand december international products estimated levels inventory distribution channel excess one month hand september plavix months inventory hand us compared months inventory hand december due loss exclusivity may expect gradual decrease inventory hand plavix occur next years product wholesale distribution channel continues worked returned levels inventory hand wholesale retail distribution channels considered assessing sales return reserves established december avaproavalide months inventory hand us compared inventory hand december due loss exclusivity march onetime increase million inventory wholesale retail distribution channels corresponding transition avaproavalide manufacturing sanofi pursuant restructured agreement levels inventory hand wholesale retail distribution channels considered assessing sales return reserves established december dafalgan analgesic product sold principally europe months inventory hand direct customers compared months inventory hand december level inventory hand primarily due ordering patterns pharmacists france fervex cold flu product months inventory hand internationally direct customers compared months inventory hand december level inventory hand decreased following peak flu season remaining inventory hand primarily attributable ordering patterns pharmacists france luftal antacid product months inventory hand internationally direct customers compared months inventory hand december level inventory hand primarily due government purchasing patterns brazil us products sold exclusively wholesalers distributors generally determined months hand estimates using inventory levels product hand amount outmovement provided three largest wholesalers account approximately total gross sales us products provided distributors factors may influence estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes businesses outside us significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely cases direct customer product level inventory ultimate patientconsumer demand outmovement data exist otherwise available developed variety methodologies estimate data including using factors historical sales made direct customers thirdparty market research data related prescription trends enduser demand accordingly rely variety methods estimate direct customer product level inventory calculate months hand factors may affect estimates include generic competition seasonality products direct customer purchases light price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing annual report disclose product levels inventory excess one month hand expected demand subject de minimis exception next quarterly report form q expenses change dollar millions vs vs cost products sold marketing selling administrative advertising product promotion research development impairment charge bms intangible asset na na incomeexpense total expenses change excess cost products sold cost products sold consists material costs internal labor overhead owned manufacturing sites thirdparty processing costs supply chain costs settlement foreign currency forward contracts used hedge forecasted intercompany inventory purchase transactions essentially costs managed global manufacturing supply organization cost products also includes royalties profit sharing attributed licensed products alliances amortization acquired developed technology costs business combinations milestone payments occur regulatory approval cost products sold vary periods result product mix particularly resulting royalties profit sharing expenses connection alliances price inflation costs attributed rationalization manufacturing sites resulting accelerated depreciation impairment charges stranded costs addition changes foreign currency may also provide volatility given high percentage total costs denominated foreign currencies cost products sold percentage net sales decrease cost products sold primarily attributed lower sales volume following loss exclusivity plavix avaproavalide resulted lower royalties connection sanofi alliance favorable foreign exchange partially offset impairment charges discussed higher amortization costs resulting amylin acquisition net amortization amylin collaboration proceeds impairment charges million recognized million related partial writedown fair value developed technology costs related nonkey product recothrom acquired acquisition zymogenetics inc zymogenetics developed technology impairment charge resulted continued competitive pricing pressures reduction undiscounted projected cash flows amount less carrying value intangible asset impairment charge calculated difference fair value asset based discounted value estimated future cash flows carrying value intangible asset remaining million impairment charge related abandonment manufacturing facility resulting outsourcing manufacturing process increase primarily attributable higher sales volume resulting additional royalties collaboration fees profit sharing expense unfavorable foreign exchange marketing selling administrative marketing selling administrative expenses consist salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs expenses attributed product manufacturing costs research development expenses expenses managed regional commercialization organizations global corporate organizations finance law information technology human resources marketing selling administrative expenses increased slightly primarily result amylin acquisition million including million related accelerated vesting stock options restricted stock units partially offset reduction salesrelated activities plavix avaproavalide marketing selling administrative expenses also impacted favorable foreign exchange increase attributed annual pharmaceutical company fee unfavorable foreign exchange higher marketing costs support new launches key products lesser extent higher bad debt expense eu charitable funding information technology expenses annual pharmaceutical company fee million million information regarding annual pharmaceutical company fee refer item businessgovernment regulation price constraints advertising product promotion advertising product promotion expenses consist related media sample direct consumer programs decrease primarily attributed lower spending promotion plavix avaproavalide abilify certain mature brands us coincide product life cycle research development research development expenses consist salary benefit costs thirdparty grants fees paid clinical research organizations supplies facility costs total research development expenses include costs discovery research preclinical development early lateclinical development drug formulation well clinical trials medical support marketed products proportionate allocations enterprisewide costs facilities information technology employee stock compensation costs appropriate costs expenses also include thirdparty licensing fees typically paid upfront well regulatory contractual milestones met certain expenses shared alliance partners based upon contractual agreements expenses managed global research development organization approximately billion total spend attributed development activities remainder attributed preclinical research activities expenses vary periods number reasons including timing upfront milestone licensing payments research development expenses increased primarily million expenses related amylin acquisition including million related accelerated vesting amylin stock options restricted stock units partially offset favorable foreign exchange net impact upfront milestone licensing payments iprd impairment charges refer specified items included nongaap financial measures amounts attributed period iprd impairment charges relate projects previously acquired medarex inc medarex acquisition inhibitex acquisition including million related fv nucleoside inhibitor reduction shinglesassociated pain resulting unfavorable clinical trial results decisions cease development increase attributed higher upfront milestone licensing payments unfavorable foreign exchange additional development costs resulting acquisition zymogenetics upfront milestone licensing payments million including million payment associated amendment intellectual property license agreement yervoy prior fda approval payments exclusive licenses develop commercialize certain programs compoundsimpairment charge bms intangible asset billion impairment charge recognized development bms formerly inx compound acquired part acquisition inhibitex treat hepatitis c virus infection discontinued interest patient safety see item financial statements note goodwill intangible assets information incomeexpense incomeexpense include year ended december dollars millions interest expense investment income provision restructuring litigation chargesrecoveries equity net income affiliates impairment loss sale manufacturing operations outlicensed intangible asset impairment gain sale product lines businesses assets income received alliance partners net pension curtailments settlements incomeexpense interest expense increased due termination interest rate swap contracts higher borrowings investment income included million gain sale auction rate securities provision restructuring primarily attributable employee termination benefits continuous improvement initiatives additional employee termination costs approximately million expected incurred result workforce reductions several european countries majority costs recognized completion discussions local workers council subject local regulations expected employee reductions primarily attributed sales force personnel resulting restructuring sanofi otsuka agreements streamlining operations due challenging market conditions europe litigation chargesrecoveries included million share apotex damages award concerning plavix partially offset increases reserves product liability pricing sales promotional matters equity net income affiliates primarily related international partnership sanofi decreased result continued impact generic competition international plavix net sales conversion certain territories optout markets impact unfavorable foreign exchange impairment loss sale manufacturing operations primarily attributed disposal manufacturing operations latina italy outlicensed intangible asset impairment charges related assets acquired medarex inc medarex zymogenetics acquisitions resulted unfavorable clinical trial results andor abandonment programs similar charges million included research development gain sale product lines businesses assets primarily related sale building mexico sale mature brands income alliance partners includes income earned sanofi partnership amortization certain upfront milestone licensing payments related alliances decrease us plavix net sales resulted lower development royalties owed sanofi pension settlement charge recognized primary us pension plan result annual lump sum payments exceeding interest service costs fourth quarter charge included acceleration portion unrecognized actuarial losses similar charges might occur future see item financial statementsnote pension postretirement postemployment liabilities detail change primarily related higher acquisition costs losses debt repurchases sales tax reimbursements gains debt repurchases higher upfront milestone licensing receipts nongaap financial measures nongaap financial measures including nongaap earnings related eps information adjusted exclude certain costs expenses gains losses specified items due significant andor unusual nature evaluated individual basis similar charges gains items recognized prior periods reasonably possible could reoccur future periods nongaap information intended portray results baseline performance include discovery development licensing manufacturing marketing distribution sale pharmaceutical products global basis enhance investors overall understanding past financial performance prospects future example nongaap earnings eps information indication baseline performance items considered us reflective ongoing results addition information among primary indicators use basis evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information intended considered isolation substitute net earnings diluted eps prepared accordance gaap specified items follows year ended december dollars millions accelerated depreciation asset impairment shutdown costs amortization acquired amylin intangible assets amortization amylin collaboration proceeds amortization amylin inventory adjustment cost products sold stock compensation accelerated vesting amylin awards process standardization implementation costs marketing selling administrative stock compensation accelerated vesting amylin awards upfront milestone licensing payments iprd impairment research development impairment charge bms intangible asset provision restructuring impairment loss sale manufacturing operations gain sale product lines businesses assets pension curtailments settlements acquisition related items litigation chargesrecoveries upfront milestone licensing receipts outlicensed intangible asset impairment loss debt repurchases incomeexpense decrease pretax income income tax items outof period tax adjustment specified tax benefitcharge income taxes decrease net earnings specified tax benefit relates capital loss deduction specified tax benefit relates releases tax reserves specified prior periods specified tax charge relates tax charge additional us taxable income earnings foreign subsidiaries previously considered indefinitely reinvested offshore reconciliations gaap nongaap follows year ended december dollars millions except per share data net earnings attributable bms gaap earnings attributable unvested restricted shares net earnings attributable bms used diluted eps calculation gaap net earnings attributable bms gaap less specified items net earnings attributable bms nongaap earnings attributable unvested restricted shares net earnings attributable bms used diluted eps calculation nongaap average common shares outstanding diluted diluted eps attributable bms gaap diluted eps attributable specified items diluted eps attributable bms nongaap income taxes million income tax benefit attributable million capital loss deduction resulting tax insolvency inhibitex impact deduction reduced effective tax rate percentage points addition impact effective tax rate substantially lower resulting primarily favorable earnings mix high low tax jurisdictions change earnings mix primarily attributed lower plavix sales million impairment charge bms intangible asset us lesser extent internal transfer intellectual property transfer selected intellectual property rights outside us existing new products part strategy place key assets closer manufacturing distribution operational decisions made favorable earnings mix high low tax jurisdictions expected continue least excluding impact impairment charge historically effective income tax rate lower us statutory rate due decision indefinitely reinvest earnings certain manufacturing operations ireland puerto rico favorable tax rates ireland puerto rico grants scheduled expire prior american taxpayer relief act act signed law january provisions act included retroactive reinstatement rd tax credit look exception result rd tax credit look exception benefit recognized first quarter detailed discussion income taxes changes effective tax rates refer item financial statementsnote income taxes noncontrolling interest noncontrolling interest primarily related plavix avaproavalide partnerships sanofi territory covering americas see item financial statementsnote alliances collaborations decrease noncontrolling interest resulted exclusivity loss us avaproavalide march plavix may increase noncontrolling interest corresponds increased net sales plavix us summary noncontrolling interest follows year ended december dollars millions sanofi partnerships noncontrolling interestpretax income taxes net earnings attributable noncontrolling interestnet taxes financial position liquidity capital resources net cashdebt position follows dollars millions cash cash equivalents marketable securities current marketable securities noncurrent total cash cash equivalents marketable securities shortterm borrowings current portion longterm debt longterm debt net cashdebt position working capital current net debt position reduction working capital resulted primarily net cash used connection acquisitions amylin inhibitex cash cash equivalents marketable securities held us approximately billion december remaining billion held primarily lowtax jurisdictions attributable earnings expected indefinitely reinvested offshore cash repatriations subject restrictions certain jurisdictions may subject withholding additional us income taxes started issuing commercial paper meet nearterm domestic liquidity requirements preparation amylin acquisition third quarter average amount commercial paper outstanding million weightedaverage interest rate maximum monthend amount commercial paper outstanding million outstanding borrowings december likely continue issue commercial paper meet domestic liquidity requirements needed investment portfolio includes noncurrent marketable securities subject changes fair value result interest rate fluctuations market factors may impact results operations investment policy places limits investments amount time maturity investments institution policy also requires investments entered corporate financial institutions meet high credit quality standards see item financial statementsnote financial instruments currently two separate billion fiveyear revolving credit facilities syndicate lenders including new facility entered july facilities provide customary terms conditions financial covenants extendable anniversary date consent lenders borrowings outstanding either revolving credit facility december connection amylin acquisition bms issued billion senior unsecured notes registered public offering consisting million aggregate principal amount notes due million aggregate principal amount notes due million aggregate principal amount notes due bms completed acquisition amylin aggregate purchase price billion bms also assumed amylins net debt contractual payment obligation lilly together totaling billion substantially repaid acquisition financed use existing cash balances issuance commercial paper longterm debt borrowings described additional regulations us could passed future could reduce results operations operating cash flow liquidity financial flexibility also continue monitor potential impact economic conditions certain european countries related impact prescription trends pricing discounts creditworthiness customers ability collect outstanding receivables direct customers currently believe economic conditions eu material impact liquidity cash flow financial flexibility mechanism limit overall credit exposures additional source liquidity sell trade receivables third parties principally wholesalers japan certain governmentbacked entities italy portugal spain sales trade receivables italy portugal spain million million million sales receivables japan million million million sales agreements allow recourse event uncollectibility retain interest underlying assets sold continue manage operating cash flows initiatives designed improve working capital items directly affected changes sales volume receivables inventories accounts payable following changes receivables inventories accounts payable resulted primarily rapid reduction plavix sales acquisition amylin timing expenditures ordinary course business trailing trailing december twelve month december twelve month dollars millions net sales net sales net trade receivables inventories accounts payable total credit ratings moodys investors service longterm shortterm credit ratings currently prime respectively longterm credit outlook remains stable standard poors sp longterm shortterm credit ratings currently respectively longterm credit outlook remains stable sp upgraded shortterm credit rating may fitch ratings fitch longterm shortterm credit ratings currently f respectively longterm credit outlook remains negative fitch lowered longterm credit rating july credit ratings considered investment grade longterm ratings designate low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm ratings designate strongest capacity timely repayment cash flows following discussion cash flow activities dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts cash disbursements activities investing activities financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items gains losses attributed investing financing activities changes operating assets liabilities resulting timing differences receipts payments cash transactions recognized results operations result changes cash operating activities reflect timing cash collections customers alliance partners payments suppliers alliance partners employees pension contributions tax payments ordinary course business billion increase operating cash flow primarily attributable preliminary proceeds billion received astrazeneca consideration entering amylin collaboration partially offset lower operating cash flows attributed plavix avaproavalide sales reductions following exclusivity loss products investing activities cash used fund acquisitions amylin billion inhibitex billion amira million including million contingent payment zymogenetics million net sales maturities marketable securities billion primarily attributed funding amylin acquisition net purchases marketable securities million billion primarily attributed timing investments time deposits corporate debt securities maturities greater days investing activities included litigation recoveries million financing activities dividend payments billion billion billion dividends declared per common share december declared quarterly dividend per common share expect pay dividend full year per share dividend decisions made quarterly basis board directors proceeds received issuance senior unsecured notes repayments debt assumed amylin acquisition billion management periodically evaluates potential opportunities repurchase certain debt securities terminate certain interest rate swap contracts prior maturity cash outflows related repurchase debt million million million proceeds termination interest rate swap contracts million million million board directors increased authorization repurchase common stock billion june common stock repurchase capacity remaining billion december cash used repurchase common stock billion billion million proceeds stock option exercises million including million cash retained excess tax benefits million including million cash retained excess tax benefits million amount proceeds vary period based upon fluctuations market value stock relative exercise price stock options factors contractual obligations payments due period contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debta operating leases purchase obligations uncertain tax positionsb longterm liabilities totalc includes estimated future interest payments shortterm longterm debt securities also includes accrued interest payable recognized consolidated balance sheets consists primarily accrued interest shortterm longterm debt well accrued periodic cash settlements derivatives b due uncertainty related timing reversal uncertain tax positions shortterm uncertain tax benefits provided table see item financial statementsnote income taxes detail c table excludes future contributions us pensions postretirement postemployment benefit plans required contributions contingent upon numerous factors including minimum regulatory funding requirements funded status plan due uncertainty future obligations excluded table contributions us international plans expected million see item financial statementsnote pension postretirement postemployment liabilities detail addition committed billion aggregate potential future research development milestone payments third parties part inlicensing development programs early stage milestones defined milestones achieved phase iii clinical trials comprised billion total committed amount late stage milestones defined milestones achieved post phase iii clinical trials comprised billion total committed amount payments agreements generally due payable upon achievement certain developmental regulatory milestones specific timing predicted addition certain royalty obligations calculated percentage net sales agreements also provide salesbased milestones aggregating billion would obligated pay alliance partners upon achievement certain sales levels also certain manufacturing development commercialization obligations connection alliance arrangements practicable estimate amount obligations see item financial statementsnote alliances collaborations information regarding alliances discussion contractual obligations see item financial statementsnote pension postretirement postemployment liabilities note financial instruments note leases sec consent order previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis maintain inventory management agreements imas us pharmaceutical wholesalers account nearly gross us sales current terms imas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three largest wholesalers currently account approximately gross us sales inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast nonus business significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent recently issued accounting standards none applicable critical accounting policies preparation financial statements requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses critical accounting policies significantly impact financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain uncertainty actual results may vary estimates accounting policies discussed audit committee board directors revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates recognize revenue persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally time shipment revenue also reduced grosstonet sales adjustments discussed involve significant estimates judgment considering legal interpretations applicable laws regulations historical experience payer channel mix eg medicare medicaid current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel estimates assessed period adjusted required revised information actual experience addition see net sales discussion analysis significant category grosstonet sales adjustments grosstonet sales adjustments following categories grosstonet sales adjustments involve significant estimates judgments information obtained external sources see net sales discussion analysis significant category grosstonet sales adjustments chargebacks related government programs us business participates programs government entities significant us department defense us department veterans affairs parties including covered entities b drug pricing program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price accounts receivable reduced estimated amount unprocessed chargeback claims attributable sale typically within two four week time lag cash discounts us certain countries cash discounts offered incentive prompt payment generally approximating sales price accounts receivable reduced estimated amount unprocessed cash discounts typically within month time lag managed healthcare rebates contract discounts rebates discounts offered managed healthcare organizations us managing prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit addition commercial plans well contract counterparties hospitals group purchasing organizations globally beginning rebates medicare part program included discount companys brandname drugs patients fall within medicare part coverage gap rebates also required us department defense tricare retail pharmacy refund program estimated amount unpaid unbilled rebates discounts presented liability million reversal estimated amount medicare part coverage gap discounts occurred receipt actual invoices medicaid rebates us businesses participates state government medicaid programs qualifying federal state government programs requiring discounts rebates participating state local government entities discounts rebates provided programs included medicaid rebate accrual retroactive january minimum rebates medicaid drug sales increased medicaid rebates also extended drugs used managed medicaid plans beginning march estimated amount unpaid unbilled rebates presented liability million reversal estimated amount managed medicaid discounts occurred receipt actual invoices sales returns products typically eligible returned six months prior twelve months product expiration accordance policy estimated returns established products determined considering historical experience factors including levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products instances expected precipitous declines demand following loss exclusivity estimated amount product returns presented liability reserves million established plavix avaproavalide december considering relevant factors well estimated future retail wholesale inventory work would occur loss exclusivity estimated returns new products determined considering historical sales return experience similar products within product line similar therapeutic category defer recognition revenue right return expires sufficient historical experience estimate sales returns developed limited circumstances typically occurs new product extension existing line product historical experience products similar therapeutic category lacking estimated levels inventory distribution channel projected demand also considered estimating sales returns new products although reflected gross net adjustment million revenue related yervoy deferred result limited returns experience use information external sources information external sources used estimate grosstonet sales adjustments estimate inventory wholesalers based projected prescription demandbased sales products historical inventory experience well analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information retirement benefits accounting pension postretirement benefit plans requires actuarial valuations based significant assumptions discount rates expected longterm rates return plan assets consultation actuaries significant assumptions others salary growth retirement turnover healthcare trends mortality rates evaluated selected based expectations actual experience remeasurement date pension expense could vary within range outcomes material effect reported earnings projected benefit obligations future cash funding actual results given year may differ estimated economic factors yield high quality corporate bonds coincides cash flows plans estimated payouts used determining discount rate citigroup pension discount curve used us plans us plans pension expense determined using weightedaverage discount rate present value benefit obligations december us pension plans determined using discount rate discount rate used determining us plans pension expense reduced additional expense would increase approximately million assumed discount rate used determining us pension plans projected benefit obligation december reduced additional projected benefit obligation would increase approximately billion expected longterm rate return plan assets estimated considering expected returns individual asset classes input external advisors also consider longterm historical returns including actual performance compared benchmarks similar investments us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increase million detailed discussion retirement benefits see item financial statementsnote pension postretirement postemployment liabilities business combinations goodwill intangible assets acquired business combinations licensing transactions billion december representing total assets assets acquired liabilities assumed recognized date acquisition respective fair values excess purchase price estimated fair values net assets acquired recognized goodwill fair value intangible assets including iprd typically determined using income method method starts forecast net cash flows risk adjusted estimated probabilities technical regulatory success iprd adjusted present value using appropriate discount rate reflects risk associated cash flow streams assets valued market participant view might different specific bms views valuation process complex requires significant input judgment using internal external sources although valuations required finalized within oneyear period must consider facts evidence available acquisition date complex judgmental matters applicable valuation process summarized unit account intangible assets valued single global assets rather multiple assets jurisdiction indication considering development stage expected levels incremental costs obtain additional approvals risks associated development amount timing benefits expected derived future expected patent lives various jurisdictions intention promote asset global brand estimated useful life asset life expected contribute meaningful cash flows determined considering pertinent matters associated asset including expected regulatory approval dates unapproved exclusivity periods legal regulatory contractual provisions well effects obsolescence demand competition economic factors including barriers entry probability technical regulatory success ptrs rate ptrs rates determined based upon industry averages considering respective programs development stage disease indication adjusted specific information data known acquisition date subsequent clinical results internal external data obtained could alter ptrs rate materially impact estimated fair value intangible asset subsequent periods leading impairment charges projections future revenues estimated considering many factors initial market opportunity pricing sales trajectories peak sales levels competitive environment product evolution future costs expenses estimated considering historical market trends market participant synergies timing level additional development costs obtain initial additional regulatory approvals maintain enhance product generally assume initial positive cash flows commence shortly receipt expected regulatory approvals typically may occur number years actual cash flows attributed project likely different assumed since projections subjected multiple factors including trial results regulatory matters could materially change ultimate commercial success asset well significantly alter costs develop respective asset commercially viable products tax rates expected future income tax effected using market participant tax rate recent valuations typically use us tax rate applicable state taxes considering jurisdiction intellectual property held location research manufacturing infrastructure also considered earnings repatriation would likely us tax consequences discount rate discount rates selected considering risks inherent future cash flows assessment assets life cycle competitive trends impacting asset including consideration technical legal regulatory economic barriers entry well expected changes standards practice indications addressed asset see item financial statementsnote acquisitions specific details values assigned assets acquired liabilities assumed acquisitions amylin inhibitex amira zymogenetics significant estimates utilized time valuations support fair values lead compounds within acquisitions include estimated phase year first discount useful life development ptrs rate projected positive dollars millions fair value rate utilized years acquisition date utilized cash flow commercialized products bydureon na na na byetta na na na symlin na na na recothrom na na na iprd bms formerly inx na phase ii metreleptin na phase iii na phase peginterferon lambda na phase iib impairment goodwill goodwill billion december goodwill tested least annually impairment enterprise level assessing qualitative factors performing quantitative analysis determining whether likely fair value exceeds carrying value examples qualitative factors assessed current year included share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year positive negative influences relevant factor assessed individually aggregate result concluded additional quantitative testing required discussion goodwill acquired inprocess research development intangible assets see item financial statementsnote accounting policiesgoodwill acquired inprocess research development intangible assets intangible assets including iprd intangible assets billion december including licenses million developed technology rights billion capitalized software million iprd million intangible assets tested impairment whenever current facts circumstances warrant review although iprd required tested least annually intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment common potential risks leading impairment include competition earlier expected loss exclusivity pricing pressures adverse regulatory changes clinical trial results delay failure obtain regulatory approval additional development costs inability achieve expected synergies higher operating costs changes tax laws macroeconomic changes complexity estimating fair value intangible assets connection impairment test similar initial valuation considering high risk nature research development industrys success rate bringing developmental compounds market iprd impairment charges likely occur future periods recognized charges billion including billion charge resulting discontinued development bms projects previously acquired medarex inc inhibitex acquisition resulting unfavorable clinical trial results additional development costs extended development periods decisions cease development also recognized charges million million related three medarex projects development ceased iprd closely monitored assessed period impairment addition iprd commercial assets also subject impairment example impairment charge million recognized related nonkey product recothrom acquired acquisition zymogenetics continuing competitive pricing pressures preliminary estimated fair value developed technology rights resulting acquisition amylin billion including billion allocated recentlylaunched single asset bydureon assets monitored changes expectations used initial valuation including revenue trends operating synergies contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability contractual claims tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies see item financial statementsnote accounting policiescontingencies note income taxes note legal proceedings contingencies income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecasts future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made deferred tax assets billion net valuation allowances billion december billion net valuation allowances billion december deferred tax assets related us federal net operating loss carryforward million us federal tax credit carryforward million recognized december net operating loss carryforward expires varying amounts beginning us federal tax credit carryforward expires varying amounts beginning realization carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although realization assured believe likely deferred tax assets realized addition deferred tax asset related us federal state capital loss million recognized december carried back three years carried forward five years realization carryforward dependent upon generating sufficient capital gains prior expiration million valuation allowance established item december taxes provided undistributed earnings foreign subsidiaries expected reinvested indefinitely offshore company completed internal reorganization certain legal entities contributed million tax charge recognized fourth quarter possible us tax authorities could assert additional material tax liabilities arising reorganization assertion occur company would vigorously challenge assertion believes would prevail however assurance result prior mead johnson nutrition company mead johnson splitoff following transactions occurred internal spinoff mead johnson shares still owned us ii conversion mead johnson class b shares class shares iii conversion mead johnson company limited liability company transactions well splitoff mead johnson exchange offer qualify taxexempt transactions internal revenue code based upon private letter ruling received internal revenue service related conversion mead johnson class b shares class shares outside legal opinions certain assumptions representations covenants mead johnson relied upon regarding future conduct business matters could affect tax treatment exchange example current tax law generally creates presumption exchange would taxable us mead johnson shareholders engage transactions result greater change stock ownership four year period beginning two years exchange offer unless established exchange offer part plan series related transactions effect change ownership internal spinoff exchange offer determined qualify tax exempt transaction transaction could subject tax exchange taxable sale us market value addition negative basis excess loss account ela existed investment stock mead johnson prior transactions received opinion outside legal counsel effect likely eliminated ela part transactions taxable income respect ela tax law area complex possible even internal spinoff exchange offer tax exempt internal revenue code irs could assert additional taxable income period respect ela could exposed additional taxes occur based upon understanding internal revenue code opinion outside legal counsel tax reserve million established reducing gain disposal mead johnson included discontinued operations agreed certain tax related indemnities mead johnson set forth tax sharing agreement example mead johnson agreed indemnify us potential tax effects resulting breach certain representations discussed well certain transactions related acquisition mead johnsons stock assets agreed indemnify mead johnson certain taxes related business prior completion ipo created part restructuring facilitate ipo established liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known discussions income taxes see item financial statementsnote accounting policiesincome taxes note income taxes special note regarding forwardlooking statements annual report including documents incorporated reference written oral statements make time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years included important factors cautionary statements included annual report particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made undertake obligation release publicly revisions forwardlooking statements result new information future events otherwise item quantitative qualitative disclosures market risk exposed market risk resulting changes currency exchange rates interest rates certain derivative financial instruments used available costeffective basis hedge underlying economic exposure financial instruments including derivatives subject counterparty credit risk considered part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant amounts revenues earnings cash flow exposed changes foreign currency rates primary net foreign currency translation exposures euro japanese yen chinese renminbi canadian dollar british pound foreign currency forward contracts used manage foreign exchange risk primarily arises certain intercompany purchase transactions designated foreign currency cash flow hedges appropriate addition exposed foreign exchange transaction risk arises nonfunctional currency denominated assets liabilities earnings denominated nonus dollar currencies foreign currency forward contracts used offset portion exposures designated hedges changes fair value derivatives recognized earnings incurred estimate appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million december realized appreciation would negatively affect earnings remaining life contracts also exposed translation risk nonus dollardenominated net assets nonus dollar borrowings used hedge foreign currency exposures net investment certain foreign affiliates designated hedges net investments effective portion foreign exchange gains losses hedges recognized part foreign currency translation component accumulated oci net investment fall equivalent value nonus debt borrowings change remeasurement basis debt would subject recognition income changes occur additional information see item financial statementsnote financial instruments interest rate risk fixedtofloating interest rate swap contracts used designated fairvalue hedges part interest rate risk management strategy contracts intended provide us appropriate balance fixed floating rate debt estimate increase basis points shortterm longterm interest rates would decrease fair value interest rate swap contracts million excluding effects counterparty credit risk realized fair value reduction would affect earnings remaining life contracts estimate increase basis points longterm interest rates would decrease fair value longterm debt million marketable securities subject changes fair value result interest rate fluctuations market factors policy invest institutions meet high credit quality standards estimate increase basis points interest rates general would decrease fair value debt security portfolio approximately million credit risk although material certain european governmentbacked entities higher risk default identified monitoring economic factors including credit ratings creditdefault swap rates debttogross domestic product ratios addition entity specific factors historically exposure limited factoring receivables deferring revenues collection cash however counterparties factoring arrangements suspended factoring receivables spanish portuguese governmentbacked entities limited factoring receivables certain italian governmentbacked entities credit exposures europe may increase future due reductions factoring arrangements ongoing sovereign debt crisis credit exposure governmentbacked trade receivables greece portugal italy spain approximately million december approximately governmentbacked entities monitor investments counterparties objective minimizing concentrations credit risk investment policy places limits amount time maturity investments individual counterparty policy also requires investments made primarily highly rated corporate financial us government government supported institutions use derivative instruments exposes us credit risk fair value derivative instrument contract positive exposed credit risk counterparty fails perform fair value derivative instrument contract negative counterparty exposed credit risk fail perform obligation terms agreements posting collateral required party whether derivatives asset liability position policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information see item financial statements note financial instruments bristolmyers squibb company consolidated statements earnings dollars shares millions except per share data item financial statements supplementary data year ended december earnings net sales cost products sold marketing selling administrative advertising product promotion research development impairment charge bms intangible asset incomeexpense total expenses earnings income taxes provision forbenefit income taxes net earnings net earnings attributable noncontrolling interest net earnings attributable bms earnings per common share basic diluted cash dividends declared per common share accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements comprehensive income dollars millions year ended december comprehensive income net earnings comprehensive incomeloss net taxes derivatives qualifying cash flow hedges unrealized gains realized gains pension postretirement benefits actuarial losses amortization settlements curtailments available sale securities unrealized gains realized gains foreign currency translation foreign currency translation net investment hedges total comprehensive incomeloss net taxes comprehensive income comprehensive income attributable noncontrolling interest comprehensive income attributable bms accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables inventories deferred income taxes prepaid expenses total current assets property plant equipment goodwill intangible assets deferred income taxes marketable securities assets total assets liabilities current liabilities shortterm borrowings current portion longterm debt accounts payable accrued expenses deferred income accrued rebates returns us foreign income taxes payable dividends payable total current liabilities pension postretirement postemployment liabilities deferred income us foreign income taxes payable deferred income taxes liabilities longterm debt total liabilities commitments contingencies note equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total bristolmyers squibb company shareholders equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities net earnings attributable noncontrolling interest depreciation amortization net deferred income taxes stockbased compensation impairment charges proceeds amylin diabetes collaboration changes operating assets liabilities receivables inventories accounts payable deferred income us foreign income taxes payable net cash provided operating activities cash flows investing activities proceeds sale maturities marketable securities purchases marketable securities additions property plant equipment capitalized software proceeds sale businesses investing activities purchase businesses net cash acquired net cash used investing activities cash flows financing activities shortterm debt borrowingsrepayments proceeds issuance longterm debt longterm debt repayments interest rate swap terminations issuances common stock common stock repurchases dividends paid net cash used financing activities effect exchange rates cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statements note accounting policies basis consolidation consolidated financial statements prepared conformity united states us generally accepted accounting principles gaap including accounts bristolmyers squibb company may referred bristolmyers squibb bms company controlled majorityowned subsidiaries intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date codevelopment cocommercialization license arrangements assessed determine whether terms provide economic control entity requiring consolidation entity entities controlled means majority voting interest referred variable interest entities arrangements material variable interest entities periods presented use estimates preparation financial statements requires use management estimates assumptions significant assumptions employed estimates used determining fair value potential impairment intangible assets sales rebate return accruals legal contingencies income taxes pension postretirement benefits actual results may differ estimated results reclassifications certain prior period amounts reclassified conform current period presentation presentation depreciation amortization consolidated statements cash flows includes depreciation property plant equipment amortization intangible assets deferred income provision restructuring equity net income affiliates litigation expense net previously presented separately consolidated statements earnings currently presented components incomeexpense revenue recognition revenue recognized persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally time shipment however certain sales nonus businesses recognized date receipt purchaser see note alliances collaborations discussion revenue recognition related alliances provisions made time revenue recognition expected sales returns discounts rebates estimated sales allowances based historical experience updated changes facts circumstances including impact applicable healthcare legislation provisions recognized reduction revenue revenue deferred right return longer exists sufficient historical experience estimate sales returns developed new product extension existing line product historical experience products similar therapeutic category income taxes provision income taxes includes income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax basis assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made recognize tax benefit uncertain tax position likely tax position sustained examination taxing authorities based technical merits position tax benefit recognized financial statements particular tax position based largest benefit likely realized upon settlement cash cash equivalents cash cash equivalents include us treasury securities government agency securities bank deposits time deposits money market funds cash equivalents consist highly liquid investments original maturities three months less time purchase recognized cost approximates fair value marketable securities investments companies marketable securities classified availableforsale date purchase reported fair value fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity investments less owned companies accounted using equity method accounting ability exercise significant influence maintained share net income losses equity investments included equity net income affiliates incomeexpense equity investments reviewed impairment assessing decline market value investment carrying value temporary considers intent ability retain investment length time extent market value less cost financial condition investee inventory valuation inventories stated lower average cost market property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation computed straightline method based estimated useful lives related assets estimated useful lives depreciable assets range years buildings years machinery equipment fixtures impairment longlived assets current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques using level fair value inputs including discounted value estimated future cash flows longlived assets held sale reported lower carrying value estimated net realizable value capitalized software eligible costs obtain internal use software significant systems projects capitalized amortized estimated useful life software insignificant costs obtain software projects expensed incurred business combinations businesses acquired consolidated upon obtaining control acquiree fair value assets acquired liabilities assumed recognized date acquisition excess purchase price estimated fair values net assets acquired recognized goodwill legal audit business valuation business acquisition costs expensed incurred goodwill acquired inprocess research development intangible assets fair value intangible assets typically determined using income method utilizes level fair value inputs market participant valuations assume global view considering potential jurisdictions indications based discounted aftertax cash flow projections risk adjusted estimated probability technical regulatory success iprd finitelived intangible assets including licenses developed technology rights iprd projects reach commercialization amortized straightline basis estimated useful life estimated useful lives determined considering period assets expected contribute future cash flows goodwill tested least annually impairment assessing qualitative factors performing quantitative analysis determining whether likely fair value net assets carrying amounts examples qualitative factors assessed include share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year relevant factor assessed individually aggregate iprd tested impairment annual basis frequently events occur circumstances change would indicate potential reduction fair values assets carrying value carrying value iprd determined exceed fair value impairment loss recognized difference finitelived intangible assets tested impairment facts circumstances suggest carrying value asset may recoverable carrying value exceeds projected undiscounted pretax cash flows intangible asset impairment loss equal excess carrying value estimated fair value discounted aftertax cash flows recognized restructuring restructuring charges recognized result actions streamline operations rationalize manufacturing facilities judgment used estimating impact restructuring plans including future termination benefits exit costs incurred actions take place actual results could vary estimates contingencies loss contingencies legal proceedings claims may occur wide range matters including government investigations shareholder lawsuits product environmental liability contractual claims tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies recognized realized legal fees expensed incurred derivative financial instruments derivatives used principally management interest rate foreign currency exposures held used trading purposes derivatives recognized fair value changes fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized earnings derivative designated cash flow hedge effective portions changes fair value derivative reported accumulated comprehensive income oci subsequently recognized earnings hedged item affects earnings cash flows classified consistent underlying hedged item derivatives designated assigned hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer probable occur gain loss immediately recognized earnings nonderivative instruments primarily euro denominated longterm debt also designated hedges net investments foreign affiliates effective portion designated nonderivative instrument recognized foreign currency translation section oci ineffective portion recognized earnings shipping handling costs shipping handling costs included marketing selling administrative expenses million million million advertising product promotion costs advertising product promotion costs expensed incurred foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized oci research development research development costs expensed incurred clinical study costs accrued service periods specified contracts adjusted necessary based upon ongoing review level effort costs actually incurred strategic alliances third parties provide rights develop manufacture market andor sell pharmaceutical products rights owned party certain research development payments alliance partners contingent upon achievement certain predetermined criteria milestone payments achieved prior regulatory approval product expensed research development milestone payments made connection regulatory approvals capitalized amortized cost products sold remaining useful life asset capitalized milestone payments tested recoverability periodically whenever events changes circumstances indicate carrying amounts may recoverable research development recognized net reimbursements connection collaboration agreements upfront preapproval milestone licensing receipts obtained development deferred amortized estimated life product income company future obligation development upfront milestone licensing receipts recognized immediately income amortization period upfront licensing milestone receipts assessed determined considering terms arrangements note business segment information bms operates single segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization supply chain organization utilized responsible development delivery products market regional commercial organizations used distribute sell product business also supported global corporate staff functions segment information consistent financial information regularly reviewed chief operating decision maker chief executive officer purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross sales three largest pharmaceutical wholesalers us percentage global gross sales follows mckesson corporation cardinal health inc amerisourcebergen corporation selected geographic area information follows net sales property plant equipment dollars millions united statesa europeb rest worldc otherd total includes puerto rico b includes russia turkey c includes japan china canada australia brazil among countries includes royaltyrelated revenues sales attributed supply agreements net sales key products follows year ended december dollars millions plavix clopidogrel bisulfate avaproavalide irbesartanirbesartanhydrochlorothiazide eliquis apixaban abilify aripiprazole reyataz atazanavir sulfate sustiva efavirenz franchise baraclude entecavir erbitux cetuximab sprycel dasatinib yervoy ipilimumab orencia abatacept nulojix belatacept onglyzakombiglyze saxagliptinsaxagliptin metformin byetta exenatide na na bydureonexenatide extendedrelease injectable suspension na na mature products net sales note alliances collaborations alliances collaborations utilized third parties development commercialization certain products collaborations include arrangements access intellectual property research development manufacturing andor commercial capabilities arrangements often entered order share risks rewards related specific program product part specific divestiture strategy unless otherwise noted operating results associated alliances collaborations generally treated follows product revenues bms sales included net sales royalties collaboration profit sharing distribution fees included cost goods sold postapproval milestone payments partners deferred amortized useful life related products cost products sold cost sharing reimbursements offset applicable operating expense payments bms attributed upfront pre approval based milestone licensing payments deferred amortized estimated useful life related products incomeexpense reduction cost products sold amylin diabetes collaboration income expenses attributed collaborations noncore activities supply manufacturing arrangements compensation optingout commercialization certain countries included incomeexpense partnerships joint ventures either consolidated accounted equity method accounting related cash receipts distributions treated operating cash flow sanofi bms agreements sanofi codevelopment cocommercialization avaproavalide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy plavix platelet aggregation inhibitor worldwide alliance operates framework two geographic territories one americas principally us canada puerto rico latin american countries australia europe asia accordingly territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries general country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place bms acts operating partner owns majority controlling interest territory covering americas australia consolidates country partnership results territory sanofis share results reflected noncontrolling interest bms recognizes net sales territory comarketing countries outside territory eg germany italy irbesartan spain greece royalties owed sanofi included cost products sold development royalties sanofi acts operating partner owns majority controlling interest territory covering europe asia bms ownership interest territory included equity net income affiliates distributions profits relating partnerships included operating activities bms sanofi separate partnership governing copromotion irbesartan us sanofi paid bms million acquisition interest irbesartan license us upon formation alliance summarized financial information related alliance follows year ended december dollars millions territory covering americas australia net sales royalty expense noncontrolling interest pretax distributions sanofi territory covering europe asia equity net income affiliates distributions bms net sales europe comarketing countries amortization incomeexpense irbesartan license fee supply activities development optout royalty incomeexpense december dollars millions investment affiliates territory covering europe asia deferred income irbesartan license fee noncontrolling interest following summarized financial information interests partnerships sanofi territory covering europe asia consolidated accounted using equity method year ended december dollars millions net sales cost products sold gross profit marketing selling administrative advertising product promotion research development incomeexpense net income current assets current liabilities cost products sold includes discovery royalties million million million paid directly sanofi expenses shared based applicable ownership percentages current assets current liabilities include approximately million million million related receivablespayables attributed cash distributions bms sanofi well intercompany balances partnerships within territory remaining current assets current liabilities consist thirdparty trade receivables inventories amounts due bms sanofi purchase inventories royalties expense reimbursements september bms sanofi restructured terms codevelopment cocommercialization agreements discussed effective january subject receipt regulatory approvals certain countries sanofi assume worldwide operations alliance exception plavix us puerto rico alliance plavix two markets continue unchanged december terms original alliance arrangements exchange rights assumed sanofi bms receive quarterly royalties january december terminal payment sanofi million end ongoing disputes companies resolved including onetime payment million bms sanofi related avalide supply disruption us accrued otsuka bms worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify treatment schizophrenia bipolar mania disorder major depressive disorder excluding certain asian countries us portion amended commercialization manufacturing agreement expires upon expected loss product exclusivity april contractual share abilify net sales recognized bms uk germany france spain bms receives thirdparty net sales countries us thirdparty customers invoiced bms behalf otsuka alliance revenue recognized abilify shipped risks rewards ownership transferred third party customers bms recognizes net sales certain countries exclusive distributor product exclusive right sell abilify bms purchases product otsuka performs finish manufacturing sale thirdparty customers bms otsuka terms amended agreement bms paid otsuka million amortized reduction net sales expected loss us exclusivity april unamortized amount included assets otsuka receives royalty based total us net sales included cost products sold otsuka responsible us expenses related commercialization abilify bms also receives additional reimbursement otsuka costs incurred bms excess resource requirements specified agreement beginning january bms receive following percentages us annual net sales net sales initially recognized adjusted reflect actual level net sales share us net sales billion billion billion billion billion billion billion billion billion excess billion us commercialization agreement amended october requiring otsuka assume full responsibility providing funding sales force efforts effective january consideration bms paid otsuka million january responsible funding certain operating expenses million million million eu otsuka reimburse bms sales force effort provided march beginning april otsuka assume responsibility providing funding sales force effort bms otsuka also entered oncology collaboration sprycel ixempra ixabepilone us japan european union eu markets oncology territory collaboration fee classified cost products sold paid otsuka based following percentages annual net sales sprycel ixempra oncology territory net sales million million million million million million billion excess billion periods otsuka contributes first million certain commercial operational expenses relating oncology products ii commercial operational expenses relating products territory excess million beginning otsuka copromotes sprycel us japan exercised right copromote top five eu markets beginning january us extension oncology collaboration include changeofcontrol provision case acquisition bms acquiring company competing product abilify new company assume abilify agreement amended oncology collaboration exists today acquiring company product competes abilify otsuka elect request acquiring company choose whether divest abilify competing product scenario abilify divested otsuka would obligated acquire rights bms abilify agreement amended agreements also provide event generic competitor abilify january bms option terminating abilify april amendment agreement previously amended remaining force bms exercise option either bms would receive payment otsuka according predetermined schedule oncology collaboration would terminate time ii oncology collaboration would continue truncated period according predetermined schedule eu agreement remained unchanged expire june countries bms exclusive right sell abilify agreement expires later april expiration applicable patent data exclusivity country addition million extension payment total milestones paid otsuka million million expensed iprd remaining million capitalized intangible assets amortized cost products sold remaining life original agreement us summarized financial information related alliance follows year ended december dollars millions abilify net sales including amortization extension payment oncology products collaboration fee expense royalty expense reimbursement operating expenses tofrom otsuka amortization incomeexpense extension payment amortization incomeexpense upfront milestone licensing payments december dollars millions assets extension payment intangible assets upfront milestone licensing payments lilly bms epidermal growth factor receptor egfr commercialization agreement eli lilly company lilly lillys acquisition imclone systems incorporated imclone codevelopment promotion erbitux necitumumab imcf us expires erbitux september bms also codevelopment copromotion rights products canada japan erbitux indicated use treatment patients metastatic colorectal cancer use treatment squamous cell carcinoma head neck egfr agreement respect erbitux sales north america lilly receives distribution fee based flat rate net sales north america plus reimbursement certain royalties paid lilly bms imclone amended codevelopment agreement merck kgaa merck provide cocommercialization erbitux japan rights agreement expire however lilly ability terminate agreement determines commercially unreasonable lilly continue erbitux received marketing approval japan use erbitux treating patients advanced recurrent colorectal cancer bms receives pretax profit merck sales erbitux japan shared equally lilly bms amortizing million license acquisition costs costs products sold bms lilly restructured egfr commercialization agreement described bms imclone relates necitumumab novel targeted cancer therapy currently phase iii development nonsmall cell lung cancer companies share cost developing potentially commercializing necitumumab us canada japan lilly maintains exclusive rights necitumumab markets november provided notice termination global codevelopment cocommercialization arrangement necitumumab imcf fully human monoclonal antibody investigated anticancer treatment discovered imclone part alliance company lilly rights returning lilly termination effective may though lilly may terminate earlier summarized financial information related alliance follows year ended december dollars millions net sales distribution fees royalty expense research development expense reimbursement lilly necitumumab amortization incomeexpense upfront milestone licensing payments commercialization expense reimbursements tofrom lilly japan commercialization profit sharing incomeexpense net december dollars millions intangible assets upfront milestone licensing payments bms acquired amylin pharmaceuticals inc amylin august see note acquisitions information amylin previously entered settlement termination agreement lilly regarding collaboration global development commercialization byetta bydureon exenatide products parties agreed transition full responsibility products amylin although transition us operations completed lilly yet transitioned nonus operations amylin september bms provided notification lilly bms assume essentially nonus operations exenatide products first half therefore terminate lillys exclusive right nonus commercialization exenatide products subject certain regulatory conditions bms responsible nonus losses incurred lilly maximum million entitled tiered royalties transition complete promissory notes assumed acquisition amylin aggregating billion repaid lilly gilead bms gilead sciences inc gilead joint venture develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen treatment human immunodeficiency virus hiv infection combining sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead us canada europe bms accounts participation us joint venture equity method accounting net sales bulk efavirenz component atripla deferred combined product sold thirdparty customers net sales efavirenz component based relative ratio average respective net selling prices truvada sustiva summarized financial information related alliance follows year ended december dollars millions net sales equity net loss affiliates astrazeneca bms astrazeneca pharmaceuticals lp whollyowned subsidiary astrazeneca entered collaboration regarding worldwide development commercialization amylins portfolio products bydureon byetta symlin metreleptin currently development arrangement based framework existing diabetes alliance agreements discussed including equal sharing profits losses arising collaboration astrazeneca indicated intent establish equal governance rights certain key strategic financial decisions regarding collaboration pending required antitrust approvals certain international markets bms received preliminary proceeds billion astrazeneca consideration entering collaboration including million included accrued expenses expected reimbursed back astrazeneca remaining billion accounted deferred income amortized reduction cost products sold prorata basis estimated useful lives related longlived assets assigned purchase price allocation primarily intangible assets weightedaverage estimated useful life years property plant equipment weightedaverage estimated useful life years net proceeds bms receive astrazeneca consideration entering collaboration subject certain adjustments including right receive additional million astrazeneca exercises option equal governance rights bms astrazeneca agreed share certain tax attributes related amylin collaboration preliminary proceeds billion bms received astrazeneca included million related sharing certain tax attributes addition bms continues maintain two worldwide diabetes codevelopment cocommercialization agreements astrazeneca onglyza kombiglyze xr saxagliptin metformin hydrochloride extendedrelease komboglyze saxagliptin metformin immediaterelease marketed eu forxiga dapagliflozin agreements saxagliptin exclude japan document unless specifically noted refer kombiglyze komboglyze kombiglyze forxiga approved eu november onglyza forxiga discovered bms kombiglyze codeveloped astrazeneca companies jointly develop clinical marketing strategy share commercialization expenses profits losses equally global basis also share development costs exception forxiga development costs japan borne astrazeneca bms manufactures products bms opted decline involvement cocommercialization products certain countries bms global commercialization network instead receives compensation based net sales recorded astrazeneca countries bms received million upfront milestone licensing payments related saxagliptin date could receive additional million salesbased milestones bms also received million upfront milestone licensing payments related dapagliflozin date including million received january could potentially receive additional million development regulatory milestones additional million salesbased milestones bms entitled reimbursements capital expenditures related amylin summarized financial information related alliances follows year ended december dollars millions net sales profit sharing expense commercialization expense reimbursements tofrom astrazeneca research development expense reimbursements tofrom astrazeneca amortization incomeexpense upfront milestone licensing payments recognized cost products sold incomeexpense upfront milestone licensing payments received amylinrelated products saxagliptin dapagliflozin december dollars millions deferred income upfront milestone licensing payments amylinrelated products saxagliptin dapagliflozin pfizer bms pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement eliquis anticoagulant discovered bms prevention treatment atrial fibrillation arterial thrombotic conditions eliquis approved us japan december pfizer funds development costs initial development plan effective january companies jointly develop clinical marketing strategy share commercialization expenses profits equally global basis certain countries bms global commercialization network pfizer commercialize eliquis alone pay compensation bms based percentage net sales bms manufactures product bms received million upfront milestone licensing payments eliquis date including million received february could receive additional million development regulatory milestones payments deferred amortized estimated useful life products income summarized financial information related alliance follows year ended december dollars millions net sales commercialization expense reimbursements tofrom pfizer research development reimbursements tofrom pfizer amortization incomeexpense upfront milestone licensing payments upfront milestone licensing payments received december dollars millions deferred income upfront milestone licensing payments valeant bms pharmaswiss sa whollyowned subsidiary valeant pharmaceuticals international inc valeant entered collaboration certain mature brand products europe connection collaboration valeant responsible marketing promotion distribution sale products related regulatory matters covered territory bms responsible maintenance products intellectual property supply products collaboration expires december time valeant right purchase trademarks intellectual property price determined based multiple sales right exercised rights transferred valeant collaboration period revert back bms consideration entering collaboration bms received million start collaboration period allocated license rights transferred valeant million option purchase remaining assets end collaboration million allocation based estimated fair value option elements considering various market factors including analysis estimated excess fair value mature brands business potential purchase price option purchase trademarks intellectual property exercised december fair value option recorded liability changes estimated fair value option liability recognized results operations remaining million recognized alliance revenue throughout term collaboration bms also recognize revenue collaboration period supply product provide certain information technology regulatory order processing distribution transitional services exchange fee first six months collaboration note acquisitions amylin pharmaceuticals inc acquisition august bms completed acquisition outstanding shares amylin biopharmaceutical company focused discovery development commercialization innovative medicines treat diabetes metabolic diseases acquisition costs million included expenses bms obtained full us commercialization rights amylins two primary commercialized assets bydureon onceweekly diabetes treatment byetta daily diabetes treatment glucagonlike peptide glp receptor agonists approved certain countries improve glycemic control adults type diabetes bms also obtained full commercialization rights symlin pramlintide acetate amylinomimetic approved us adjunctive therapy mealtime insulin treat diabetes goodwill generated acquisition primarily attributed expansion diabetes franchise iprd attributed metreleptin analog human hormone leptine studied developed treatment diabetes andor hypertriglyceridemia pediatric adult patients inherited acquired lipodystrophy estimated useful life cash flows utilized value metreleptin assumed initial positive cash flows commence shortly expected receipt regulatory approvals subject trial results inhibitex inc acquisition february bms completed acquisition outstanding shares inhibitex inc inhibitex clinicalstage biopharmaceutical company focused developing products prevent treat serious infectious diseases acquisition costs million included expense bms obtained inhibitexs lead asset inx oral nucleotide polymerase nsb inhibitor phase ii development treatment chronic hepatitis c virus infections goodwill generated acquisition primarily attributed potential offer full portfolio therapy choices hepatitis virus infections well provide additional levels sustainability bmss virology pipeline iprd primarily attributed inx inx expected effective used combination therapy assumed market participants would inherently maintain franchise synergies attributed maximizing cash flows existing virology pipeline assets cash flows utilized value inx included synergies also assumed initial positive cash flows commence shortly expected receipt regulatory approvals subject trial results august company discontinued development inx interest patient safety result company recognized noncash pretax impairment charge billion related iprd intangible asset third quarter information discussion impairment charge see note goodwill intangible assets amira pharmaceuticals inc acquisition september bms completed acquisition outstanding shares amira pharmaceuticals inc amira million cash plus three separate contingent million payments due upon achievement certain development salesbased milestones first contingent payment made fourth quarter purchase price amira includes estimated fair value total contingent consideration million recorded liabilities acquisition costs million included expense amira privatelyheld biotechnology company primarily focused discovery development therapeutic products treatment cardiovascular fibrotic inflammatory diseases acquisition provides bms full rights develop commercialize completed phase clinical studies remainder amira lysophosphatidic acid receptor antagonist program researchers fibrotic expertise preclinical autotaxin program goodwill generated acquisition primarily attributed acquired scientific expertise fibrotic diseases allowing expansion new therapeutic class contingent liability estimated utilizing model assessed probability achieving milestone discounted amount potential payment based expected timing estimates used evaluating contingent liability consistent used evaluating acquired iprd discount rate payment consistent market debt yields noncallable publiclytraded bonds bms similar maturities estimated potential payment dates fair value measurement based significant inputs observable market therefore represents level measurement zymogenetics inc acquisition october bms completed acquisition outstanding shares common stock zymogenetics inc zymogenetics october acquisition costs million included expense zymogenetics focused developing commercializing therapeutic proteinbased products treatment human diseases companies collaborated development peginterferon lambda novel interferon phase iib development acquisition date treatment hepatitis c virus infection acquisition provides company full rights develop commercialize peginterferon lambda also brings proven capabilities therapeutic proteins revenue recothrom fda approved specialty surgical biologic goodwill generated acquisition primarily attributed full ownership rights peginterferon lambda final purchase price allocation zymogenetics amira inhibitex preliminary purchase price allocation pending final valuation intangible assets deferred income taxes amylin follows dollars millions identifiable net assets amylin inhibitex amira zymogenetics cash marketable securities inventory property plant equipment developed technology rights iprd assets debt obligations liabilities deferred income taxes total identifiable net assets goodwill purchase price allocated cash paid acquisition amylin included payments million outstanding common stockholders million holders stock options restricted stock units including million attributed accelerated vesting accounted stock compensation expense third quarter results operations acquired companies included consolidated financial statements acquisition date revisions goodwill preliminary estimates september amylin relate primarily adjustment preliminary amount allocated fair value acquired iprd decrease million based additional information obtained related future cash flow projections net resulting deferred tax adjustment million pro forma supplemental financial information provided impacts acquisitions material operating results year acquisition goodwill iprd intangible assets valued acquisitions nondeductible tax purposes note incomeexpense incomeexpense includes year ended december dollars millions interest expense investment income provision restructuring see note litigation chargesrecoveries equity net income affiliates impairment loss sale manufacturing operations outlicensed intangible asset impairment gain sale product lines businesses assets income received alliance partners net pension curtailments settlements incomeexpense note restructuring following provision restructuring year ended december dollars millions employee termination benefits exit costs provision restructuring restructuring charges included termination benefits workforce reductions manufacturing selling administrative research development personnel across geographic regions approximately following table represents activity employee termination exit cost liabilities year ended december dollars millions liability january charges change estimates provision restructuring foreign currency translation amylin acquisition spending liability december note income taxes provisionbenefit income taxes consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provisionbenefit effective tax rate reconciliation effective tax rate us statutory federal income tax rate earnings income taxes dollars millions earnings income taxes us nonus total us statutory rate nontax deductible annual pharmaceutical company fee tax effect foreign subsidiaries earnings previously considered indefinitely reinvested offshore foreign tax effect certain operations ireland puerto rico switzerland state local taxes net valuation allowance us federal state foreign contingent tax matters us federal research development tax credit us tax effect capital losses foreign change effective tax rate due tax benefit million attributable capital loss deduction resulting tax insolvency inhibitex favorable earnings mix high low tax jurisdictions primarily attributed lower plavix sales million impairment charge bms intangible asset us lesser extent internal transfer intellectual property partially offset contingent tax matters resulted million charge million benefit unfavorable impact current year rate delay legal enactment research development tax credit extended december changes prior period estimates upon finalizing us tax returns resulting million benefit change effective tax rate due million charge recognized fourth quarter resulted primarily additional us taxable income earnings foreign subsidiaries previously considered indefinitely reinvested offshore changes prior period estimates upon finalizing us tax returns resulting million benefit million charge higher tax benefits contingent tax matters primarily related effective settlements remeasurements uncertain tax positions million million partially offset unfavorable earnings mix high low tax jurisdictions compared prior year nontax deductible annual pharmaceutical company fee effective january tax impact million outofperiod tax adjustment million previously unrecognized net deferred tax assets primarily attributed deferred profits related certain alliances december material prior periods american taxpayer relief act act signed law january among provisions act retroactive reinstatement rd tax credit look thru exception result rd tax credit look thru exception benefit recognized first quarter deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions deferred tax assets foreign net operating loss carryforwards milestone payments license fees deferred income us capital losses us federal net operating loss carryforwards pension postretirement benefits state net operating loss credit carryforwards intercompany profit inventory items us federal tax credit carryforwards foreign deferred tax assets sharebased compensation legal settlements repatriation foreign earnings total deferred tax assets valuation allowance net deferred tax assets deferred tax liabilities depreciation repatriation foreign earnings acquired intangible assets total deferred tax liabilities deferred tax assets net recognized deferred income taxes current deferred income taxes noncurrent us foreign income taxes payable current deferred income taxes noncurrent total us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning us federal tax credit carryforwards expire varying amounts beginning realization us federal tax credit carryforwards dependent generating sufficient domesticsourced taxable income prior expiration capital loss available million carried back carried forward foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives management established valuation allowance deferred tax asset likely realized december valuation allowance million established following items million primarily foreign net operating loss tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal net operating loss carryforwards million us federal capital losses foreign holding companies net operating losses corresponding valuation allowances included increase million result statutory impairment charges required consolidated net earnings foreign holding companies higher asset basis statutory purposes basis used consolidated financial statements due internal reorganization certain legal entities prior periods changes valuation allowance follows year ended december dollars millions balance beginning year provision utilization foreign currency translation acquisitions balance end year income tax payments million million million current tax benefit realized result stock related compensation credited capital excess par value stock million million million us taxes provided approximately billion undistributed earnings foreign subsidiaries undistributed earnings indefinitely invested offshore december additional tax provisions required earnings repatriated future us earnings determined remitted foreseeable future due complexities tax laws assumptions would made practicable estimate amounts income taxes provided result bms favorable tax rates ireland puerto rico grants scheduled expire prior internal reorganization certain legal entities resulted million charge possible us tax authorities could assert additional material tax liabilities arising reorganization bms would vigorously challenge assertion occur believes would prevail however assurance result business conducted various countries throughout world subject tax numerous jurisdictions significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported requiring several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation abovea reconciliation beginning ending amount gross unrecognized tax benefits follows year ended december dollars millions balance beginning year gross additions tax positions related current year gross additions tax positions related prior years gross additions tax positions assumed acquisitions gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year additional information regarding unrecognized tax benefits follows year ended december dollars millions unrecognized tax benefits recognized would impact effective tax rate accrued interest accrued penalties interest expensebenefit penalty expensebenefit uncertain tax benefits reduce deferred tax assets extent uncertainty directly related asset otherwise recognized either current non current us foreign income taxes payable accrued interest penalties payable unrecognized tax benefits included either current noncurrent us foreign income taxes payable interest penalties related unrecognized tax benefits included income tax expense bms currently examination number tax authorities including limited major tax jurisdictions listed table proposed adjustments tax issues transfer pricing certain tax credits deductibility certain expenses bms estimates reasonably possible total amount unrecognized tax benefits december decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits primarily settlement related involve payment additional taxes adjustment certain deferred taxes andor recognition tax benefits bms also anticipates reasonably possible new issues raised tax authorities may require increases balance unrecognized tax benefits however estimate increases reasonably made time bms believes adequately provided open tax years tax jurisdiction following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico note earnings per share year ended december amounts millions except per share data net earnings attributable bms earnings attributable unvested restricted shares net earnings attributable bms common shareholders earnings per share basic weightedaverage common shares outstanding basic contingently convertible debt common stock equivalents incremental shares attributable sharebased compensation plans weightedaverage common shares outstanding diluted earnings per share diluted antidilutive weightedaverage equivalent shares stock incentive plans note financial instruments financial instruments include cash cash equivalents marketable securities accounts receivable payable debt instruments derivatives carrying amount receivables accounts payable approximates fair value due short term maturity changes currency exchange rates interest rates create exposure market risk certain derivative financial instruments used available cost effective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur derivative financial instruments used trading purposes financial instruments subject counterparty credit risk considered part overall fair value measurement counterparty credit risk monitored ongoing basis mitigated limiting amounts outstanding individual counterparty utilizing conventional derivative financial instruments entering agreements counterparties meet high credit quality standards consolidated financial statements would materially impacted counterparty failed perform according terms agreement collateral required party whether derivatives asset liability position terms agreements fair value measurements fair values financial instruments classified one following categories level inputs utilize nonbinding quoted prices unadjusted active markets accessible measurement date identical assets liabilities fair value hierarchy gives highest priority level inputs instruments include us treasury securities level inputs utilize observable prices similar instruments nonbinding quoted prices identical similar instruments markets active observable inputs corroborated market data substantially full term assets liabilities instruments include corporate debt securities commercial paper federal deposit insurance corporation fdic insured debt securities certificates deposit money market funds foreign currency forward contracts interest rate swap contracts equity funds fixed income funds longterm debt additionally certain corporate debt securities utilize thirdparty matrix pricing model uses significant inputs corroborated market data substantially full term assets equity fixed income funds primarily invested publicly traded securities valued respective net asset value underlying investments significant unfunded commitments restrictions redemptions related equity fixed income funds december level derivative instruments valued using london interbank offered rate libor euro interbank offered rate euribor yield curves less credit valuation adjustments observable forward foreign exchange rates reporting date valuations derivative contracts may fluctuate considerably period toperiod due volatility underlying foreign currencies underlying interest rates driven market conditions duration contract credit adjustment volatility may significant impact valuation interest rate swaps due changes counterparty credit ratings credit default swap spreads level unobservable inputs used little market data available valuation models auction rate security ars floating rate security frs portfolio based expected cash flow streams collateral values including assessments counterparty credit quality default risk underlying security discount rates overall capital market liquidity fair value ars determined using internally developed valuation based part indicative bids received underlying assets security evidence fair value ars private placement security rated bbb standard poors december represents interests insurance securitizations due current lack active market frs general lack transparency underlying assets qualitative analysis relied upon value frs including discussions brokers fund managers default risk underlying security overall capital markets liquidity availableforsale securities cash equivalents following table summarizes availableforsale securities december unrealized unrealized gain loss gainloss amortized accumulated accumulated fair fair value dollars millions cost oci oci income value level level level december marketable securities certificates deposit corporate debt securities us treasury securities equity funds fixed income funds ars frs total marketable securities december marketable securities certificates deposit corporate debt securities commercial paper us treasury securities fdic insured debt securities ars frs total marketable securities following table summarizes classification availableforsale securities consolidated balance sheet december dollars millions current marketable securities noncurrent marketable securities total marketable securities money market funds securities aggregating million million december respectively included cash cash equivalents valued using level inputs cash cash equivalents maintained foreign currencies million december subject currency rate risk december million noncurrent available sale corporate debt securities frs mature within five years auction rate securities mature beyond years change fair value investments equity fixed income funds recognized incomeexpense designed offset changes fair value certain employee retirement benefits following table summarizes activity financial assets utilizing level fair value measurements dollars millions fair value january sales unrealized gains fair value december qualifying hedges nonqualifying derivatives following summarizes fair value outstanding derivatives december december fair value fair value dollars millions balance sheet location notional level notional level derivatives designated hedging instruments interest rate swap contracts assets foreign currency forward contracts assets foreign currency forward contracts accrued expenses cash flow hedges foreign currency forward contracts primarily utilized hedge forecasted intercompany inventory purchase transactions certain foreign currencies forward contracts designated cash flow hedges effective portion changes fair value temporarily reported accumulated oci recognized earnings hedged item affects earnings notional amount outstanding foreign currency forward contracts primarily attributed euro million japanese yen million december net gains foreign currency forward contracts qualifying cash flow hedge accounting expected reclassified cost products sold within next two years including million pretax gains reclassified within next months cash flow hedge accounting discontinued forecasted transaction longer probable occurring originally forecasted date days thereafter hedge longer effective assessments determine whether derivatives designated qualifying hedges highly effective offsetting changes cash flows hedged items performed inception quarterly basis ineffective portion change fair value included current period earnings earnings impact related discontinued cash flow hedges hedge ineffectiveness significant periods presented net investment hedges nonus dollar borrowings million million designated hedge foreign currency exposures net investment certain foreign affiliates borrowings designated net investment hedges recognized long term debt effective portion foreign exchange gains losses remeasurement debt recognized foreign currency translation component accumulated oci related offset long term debt fair value hedges fixedtofloating interest rate swap contracts designated fair value hedges used part interest rate risk management strategy create appropriate balance fixed floating rate debt swaps underlying debt benchmark risk hedged recorded fair value effective interest rate paid fixedtofloating interest rate swaps onemonth libor december plus interest rate spread ranging underlying swap terminated prior maturity fair value basis adjustment underlying debt instrument amortized earnings reduction interest expense remaining life debt fixedtofloating interest rate swap contracts billion notional amount billion notional amount terminated generating total proceeds million including accrued interest million fixedtofloating interest rate swap contracts million notional amount million notional amount terminated generating total proceeds million including accrued interest million nonqualifying foreign exchange contracts foreign currency forward contracts used offset exposure foreign currencydenominated monetary assets liabilities earnings primary objective contracts protect us dollar value foreign currencydenominated monetary assets liabilities earnings effects volatility foreign exchange rates might occur prior receipt settlement us dollars contracts designated hedges adjusted fair value incomeexpense occur substantially offset change fair value underlying foreign currency denominated monetary asset liability earnings effect nonqualifying hedges earnings significant periods presented debt obligations shortterm borrowings current portion longterm debt includes december dollars millions bank drafts shortterm borrowings current portion longterm debt total longterm debt current portion long term debt includes december dollars millions principal value notes due notes due euro notes due euro notes due notes due notes due notes due notes due notes due debentures due debentures due debentures due maturing subtotal adjustments principal value fair value interest rate swaps unamortized basis adjustment swap terminations unamortized bond discounts total current portion longterm debt longterm debt included current portion longterm debt million floating rate convertible senior debentures due redeemed holders par september fundamental change ownership occurs debentures callable par time company debentures current conversion price equal conversion rate shares principal amount subject certain antidilutive adjustments third quarter billion senior unsecured notes issued million aggregate principal amount notes due million aggregate principal amount notes due million aggregate principal amount notes due registered public offering interest notes paid semiannually notes rank equally right payment bmss existing future senior unsecured indebtedness bms may redeem notes whole part time predetermined redemption price net proceeds note issuances million net discount million deferred loan issuance costs million average amount commercial paper outstanding million weightedaverage interest rate maximum month end amount commercial paper outstanding million outstanding borrowings december substantially billion debt obligations assumed acquisition amylin repaid third quarter including promissory note lilly respect revenue sharing obligation amylin senior notes due principal value longterm debt obligations million december million due million due million due million due remaining million due thereafter fair value longterm debt million million december respectively estimated based upon quoted market prices similar debt instruments fair value shortterm borrowings approximates carrying value due short maturities debt instruments debt repurchase activity follows dollars millions principal amount carrying value repurchase price notional amount interest rate swaps terminated swap termination proceeds total gainloss interest payments million million million net amounts related interest rate swap contracts bms currently two separate billion fiveyear revolving credit facilities syndicate lenders including new facility received july financial covenants either facility borrowings outstanding either revolving credit facility december december million financial guarantees provided form standby letters credit performance bonds standby letters credit issued financial institutions support guarantees made bms affiliates various obligations performance bonds issued support range ongoing operating activities including sale products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority outstanding financial guarantees expire within year expected funded note receivables receivables include december dollars millions trade receivables less allowances net trade receivables alliance partners receivables prepaid refundable income taxes miscellaneous receivables receivables receivables netted deferred income related alliance partners recognition income result alliance partner receivables deferred income reduced million million december respectively additional information regarding alliance partners see note alliances collaborations nonus receivables sold nonrecourse basis million million million aggregate receivables three pharmaceutical wholesalers us represented total trade receivables december respectively changes allowances bad debt chargebacks cash discounts follows year ended december dollars millions balance beginning year provision utilization balance end year note inventories inventories include december dollars millions finished goods work process raw packaging materials inventories inventories expected remain onhand beyond one year million december million december included noncurrent assets note property plant equipment property plant equipment includes december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipment depreciation expense million million million note goodwill intangible assets changes carrying amount goodwill follows december dollars millions carrying amount goodwill january acquisitions amira inhibitex amylin carrying amount goodwill december includes outofperiod adjustment correct purchase price allocation september medarex acquisition million contingent milestone payment prior acquisition medarex purchase price adjustment decreased intangible assets million increased deferred tax assets million goodwill million effect adjustment material current prior periods intangible assets include december december gross net gross net estimated carrying accumulated carrying carrying accumulated carrying dollars millions useful lives amount amortization amount amount amortization amount licenses years developed technology rights years capitalized software years total finitelived intangible assets iprd total intangible assets changes intangible assets follows dollars millions intangible assets carrying amount january capitalized software additions acquisitions amortization expense impairment charges intangible assets net carrying amount december annual amortization expense intangible assets expected approximately million million million million million million thereafter bms announced discontinued development bms formerly known inx nucleotide polymerase nsb inhibitor phase ii development treatment hepatitis c virus infection august decision made interest patient safety based rapid thorough ongoing assessment patients phase ii study voluntarily suspended august bms acquired bms acquisition inhibitex february result termination development program million pretax impairment charge recognized iprd intangible asset impairment charge million recognized related partial writedown fair value developed technology costs related nonkey product recothrom acquired acquisition zymogenetics developed technology impairment charge resulted continued competitive pricing pressures note accrued expenses accrued expenses include december dollars millions employee compensation benefits royalties accrued research development restructuring current pension postretirement benefits accrued litigation total accrued expenses note sales rebates return accruals reductions trade receivables accrued rebates returns liabilities follows december dollars millions chargebacks related government programs cash discounts reductions trade receivables managed healthcare rebates contract discounts medicaid rebates sales returns adjustments accrued rebates returns note deferred income deferred income includes december dollars millions upfront milestone licensing receipts atripla deferred revenue gain saleleaseback transactions total deferred income current portion noncurrent portion upfront milestone licensing receipts amortized expected life product see note alliances collaborations information pertaining revenue recognition transactions including billion proceeds received astrazeneca related amylin collaboration deferred gains several saleleaseback transactions amortized remaining lease terms related facilities deferred income amortization million million million note equity capital common stock excess treasury stock par value retained noncontrolling dollars shares millions shares par value stock earnings shares cost interest balance january net earnings cash dividends declared stock repurchase program employee stock compensation plans distributions balance december net earnings cash dividends declared stock repurchase program employee stock compensation plans comprehensive income attributable noncontrolling interest distributions balance december net earnings cash dividends declared stock repurchase program employee stock compensation plans comprehensive income attributable noncontrolling interest distributions balance december treasury stock recognized cost reacquire shares shares issued treasury recognized utilizing firstin firstout method may board directors authorized repurchase billion common stock june increased authorization repurchase common stock additional billion repurchases may made either open market private transactions including repurchase plans established accordance rule b securities exchange act stock repurchase program expiration date may suspended discontinued time noncontrolling interest primarily related plavix avaproavalide partnerships sanofi territory covering americas net earnings attributable noncontrolling interest presented net taxes million million million corresponding increase provision income taxes distribution partnership profits sanofi sanofis funding ongoing partnership operations occur routine basis activity includes pretax income distributions related partnerships components comprehensive incomeloss oci follows dollars millions pretax tax tax year ended december derivatives qualifying cash flow hedgesa unrealized gains realized gains derivatives qualifying cash flow hedges pension postretirement benefitsb actuarial losses amortization settlements curtailments pension postretirement benefits available sale securities unrealized gains foreign currency translation year ended december derivatives qualifying cash flow hedgesa unrealized gains realized gains derivatives qualifying cash flow hedges pension postretirement benefitsb actuarial losses amortization settlements curtailments pension postretirement benefits available sale securities unrealized gains foreign currency translation year ended december derivatives qualifying cash flow hedgesa unrealized gains realized gains derivatives qualifying cash flow hedges pension postretirement benefitsb actuarial losses amortization settlements curtailments pension postretirement benefits available sale securities unrealized gains realized gains available sale securitiesc foreign currency translation realized gainslosses derivatives qualifying effective hedges recognized costs products sold b see item financial statementsnote pension postretirement postemployment liabilities detail c realized gainslosses available sale securities recognized incomeexpense accumulated balances related component comprehensive incomeloss oci net taxes follows december dollars millions derivatives qualifying cash flow hedges pension postretirement benefits available sale securities foreign currency translation accumulated comprehensive incomeloss note pension postretirement postemployment liabilities company certain subsidiaries sponsor defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan covers us employees represents approximately consolidated pension plan assets obligations funding policy contribute least minimum amount required employee retirement income security act erisa plan benefits based primarily participants years credited service final average compensation plan assets consist principally equity fixedincome securities comprehensive medical group life benefits provided substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries outside us net periodic benefit cost defined benefit pension postretirement benefit plans includes pension benefits benefits dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service costbenefit amortization net actuarial loss curtailments settlements special termination benefits total net periodic benefit cost million pension settlement charge recognized primary us pension plan result annual lump sum payments exceeding interest service costs fourth quarter charge included acceleration portion unrecognized actuarial losses net actuarial loss prior service cost million expected amortized accumulated oci net periodic benefit cost pension postretirement benefit plans changes defined benefit postretirement benefit plan obligations assets funded status amounts recognized consolidated balance sheets follows pension benefits benefits dollars millions benefit obligations beginning year service costbenefits earned year interest cost plan participants contributions curtailments settlements plan amendments actuarial lossesgains retiree drug subsidy benefits paid exchange rate lossesgains benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions plan participants contributions settlements retiree drug subsidy benefits paid exchange rate gainslosses fair value plan assets end year funded status assetsliabilities recognized assets accrued expenses pension postretirement liabilities funded status recognized accumulated comprehensive loss net actuarial loss net obligation adoption prior service costbenefit total accumulated benefit obligation defined benefit pension plans million million december respectively additional information related pension plans follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets actuarial assumptions weightedaverage assumptions used determine benefit obligations december follows pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit cost years ended december follows pension benefits benefits discount rate expected longterm return plan assets rate compensation increase yield high quality corporate bonds matches duration benefit obligations used determining discount rate citigroup pension discount curve used developing discount rate us plans several factors considered developing expected return plan assets including longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualized returns us pension plans follows years years years pension postretirement liabilities increased million december corresponding charge comprehensive income result actuarial losses attributed benefit obligation million partially offset higher expected return plan assets million actuarial losses resulted prevailing equity fixed income market conditions reduction interest rates expected return plan assets determined using expected rate return calculated value assets referred marketrelated value approximates fair value plan assets december differences assumed actual returns amortized marketrelated value straightline basis threeyear period gains losses resulted changes actuarial assumptions changes discount rate differences assumed actual experience differences actual expected return plan assets gains losses except differences amortized market related value amortized extent exceed higher marketrelated value projected benefit obligation respective plan result approximately million related pension benefits expected amortized majority remaining actuarial losses amortized life expectancy plans participants us plans years expected remaining service periods plans cost products sold research development marketing selling administrative expenses appropriate assumed healthcare cost trend rates december follows healthcare cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate assumed healthcare cost trend rates effect amounts reported healthcare plans onepercentagepoint change assumed healthcare cost trend rates would following effects percentage percentage dollars millions point increase point decrease effect total service interest cost effect postretirement benefit obligation plan assets fair value pension postretirement plan assets asset category december follows december december dollars millions level level level total level level level total equity securities equity funds fixed income funds corporate debt securities venture capital limited partnerships government mortgage backed securities us treasury agency securities shortterm investment funds insurance contracts event driven hedge funds collateralized mortgage obligation bonds state municipal bonds asset backed securities real estate cash cash equivalents total plan assets fair value investment valuation policies per investment class follows level inputs utilize quoted prices unadjusted active markets accessible measurement date identical assets liabilities fair value hierarchy gives highest priority level inputs instruments include equity securities equity funds fixed income funds publicly traded national securities exchange us treasury agency securities cash cash equivalents cash cash equivalents highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement level inputs include observable prices similar instruments quoted prices identical similar instruments markets active observable inputs corroborated market data substantially full term assets liabilities equity funds fixed income funds event driven hedge funds shortterm investment funds classified level within fair value hierarchy valued net asset value shares held year end significant unfunded commitments restrictions redemptions related investments valued nav december corporate debt securities government mortgage backed securities collateralized mortgage obligation bonds asset backed securities us treasury agency securities state municipal bonds real estate interests classified level within fair value hierarchy valued utilizing observable prices similar instruments quoted prices identical similar instruments markets active level unobservable inputs used little market data available equity funds venture capital limited partnership investments classified level within fair value hierarchy valued estimated fair value estimated fair value based fair value underlying investment values cost plus minus accumulated earnings losses approximates fair value insurance contract interests carried contract value approximates estimated fair value based fair value underlying investment insurance company insurance contracts held certain foreign pension plans valuation models corporate debt securities collateralized mortgage obligation bonds asset backed securities classified level within fair value hierarchy based estimated bids brokers thirdparty vendor sources utilize expected cash flow streams collateral values including assessments counterparty credit quality default risk discount rates overall capital market liquidity following summarizes activity financial assets utilizing level fair value measurements venture capital limited insurance dollars millions partnerships contracts total fair value january purchases sales settlements realized lossesgains unrealized gainslosses fair value december purchases sales settlements realized lossesgains unrealized gainslosses fair value december investment strategy emphasizes equities order achieve higher expected returns lower expenses required cash contributions longterm target asset allocation public equity us international private equity fixed income maintained us pension plans investments well diversified within three major asset categories approximately us pension plans equity investments actively managed venture capital limited partnerships typically valued three month lag bms company common stock represents less plan assets december contributions contributions us pension plans million million million contributions international pension plans million million million aggregate contributions us international plans expected million estimated future benefit payments pension dollars millions benefits benefits years savings plan principal defined contribution plan bristolmyers squibb savings investment program contribution based employee contributions level company match expense related plan million million million post employment benefit plan postemployment liabilities longterm disability benefits million million december respectively expense related benefits million million termination indemnity plans statutory termination obligations recognized undiscounted basis assuming employee termination measurement date liability recognized obligations million million december respectively note employee stock benefit plans may shareholders approved stock award incentive plan plan replaced stock incentive plan shares common stock reserved issuance pursuant stock plans options conversions preferred stock million december shares available granted active plans adjusted combination plans million december shares stock option exercise share unit vesting issued treasury stock shares actually delivered participants connection award restrictions lapsed reduce number shares reserved shares tendered prior year pay purchase price options shares previously utilized satisfy withholding tax obligations upon exercise continue available reserved executive officers key employees may granted options purchase common stock less market price date option granted options generally become exercisable ratably years maximum term years additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price common stock may granted key employees subject restrictions continuous employment restrictions expire four year period date grant compensation expense recognized vesting period stock unit right receive stock end specified vesting period voting rights market share units granted certain executives beginning vesting conditioned upon continuous employment vesting date payout factor equals least payout factor share price vesting date divided share price award date maximum share price used payout factor calculated using average closing prices grant vest date nine trading days immediately preceding grant vest date vesting occurs ratably four years longterm performance awards three year cycle delivered form target number performance share units number shares ultimately issued calculated based actual performance compared earnings targets performance criteria established beginning performance period awards annual goals maximum payout threshold targets met performance period payment made plan annual period vesting occurs end three year period stockbased compensation expense based awards ultimately expected vest recognized vesting period acceleration unvested stock options restricted stock units connection acquisition amylin resulted stockbased compensation expense forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates stockbased compensation expense follows years ended december dollars millions stock options restricted stock market share units longterm performance awards amylin stock options restricted stock units see note total stockbased compensation expense income tax benefit sharebased compensation activities follows longterm stock options restricted stock units market share units performance awards weighted number weighted number weighted number weighted number average average average average options exercise price nonvested grantdate nonvested grantdate nonvested grantdate shares thousands outstanding shares awards fair value awards fair value awards fair value balance january granted releasedexercised adjustments actual payout forfeitedcancelled balance december vested expected vest total compensation costs related sharebased payment awards yet recognized weightedaverage period awards expected recognized december follows longterm stock restricted market performance dollars millions options stock units share units awards unrecognized compensation cost expected weightedaverage period years compensation cost recognized additional information related sharebased compensation awards summarized follows amounts millions except per share data weightedaverage grant date fair value per share restricted stock units market share units longterm performance awards fair value options awards vested year stock options restricted stock units market share units longterm performance awards total intrinsic value stock options exercised year following table summarizes significant ranges outstanding exercisable options december amounts millions except per share data options outstanding options exercisable weighted weighted average weighted average weighted remaining average remaining average number contractual exercise aggregate contractual exercise aggregate outstanding life price per intrinsic number life price per intrinsic range exercise prices thousands years share value exercisable years share value aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december fair value assumptions fair value restricted stock units longterm performance awards determined based closing trading price companys common stock grant date beginning fair value performance share units granted discounted participate dividends fair value performance share units granted prior discounted using riskfree interest rate date grant participate dividends fair value market share units estimated date grant using model applying multiple input variables determine probability satisfying market conditions model uses following input variables expected volatility riskfree interest rate dividend yield expected volatility based four year historical volatility levels companys common stock current implied volatility fouryear riskfree interest rate derived federal reserve based market share units contractual term expected dividend yield based historical dividend payments note leases minimum rental commitments noncancelable operating leases primarily real estate motor vehicles effect december follows years ending december dollars millions later years total minimum rental commitments operating lease expense million million million sublease income material periods presented note legal proceedings contingencies company certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business company recognizes accruals contingencies probable liability incurred amount loss reasonably estimated matters involve patent infringement antitrust securities pricing sales marketing practices environmental commercial health safety matters consumer fraud employment matters product liability insurance coverage legal proceedings material company believes could become material described although company believes substantial defenses matters assurance increase scope pending matters future lawsuits claims government investigations legal proceedings material unless otherwise noted company unable assess outcome respective litigation able provide estimated range potential loss furthermore failure enforce patent rights would likely result substantial decreases respective product sales generic competition intellectual property plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex inc apotex since changed name apotex august apotex filed application federal court australia federal court seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september federal court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid company sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february september full court held claims patent invalid november company sanofi applied high court australia high court special leave appeal judgment full court march high court denied company sanofis request hear appeal full court decision case remanded federal court proceedings related damages expected amount damages material company plavix eu previously disclosed yes pharmaceutical development services gmbh yes pharmaceutical filed application marketing authorization germany alternate salt form clopidogrel application relied data studies originally conducted sanofi bms plavix still subject data protection eu sanofi bms filed action yes pharmaceutical partners administrative court cologne objecting marketing authorization matter currently pending although specific marketing authorizations withdrawn market resolution lawsuit expected material impact company plavix canada apotex inc april apotex filed impeachment action sanofi federal court canada alleging sanofis canadian patent patent invalid june sanofi filed defense impeachment action filed suit apotex infringement patent trial completed june december federal court canada issued decision patent invalid sanofi appealed decision though generic companies since entered market decision expected later year abilify previously disclosed otsuka filed patent infringement actions teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceuticals sun zydus pharmaceuticals usa inc zydus apotex relating us patent patent covers aripiprazole expires april including additional sixmonth pediatric exclusivity period aripiprazole comarketed company otsuka us abilify nonjury trial us district court district new jersey nj district court tevabarr apotex completed august november nj district court upheld validity enforceability patent maintaining main patent protection abilify us april nj district court also ruled defendants generic aripiprazole product infringed patent permanently enjoined engaging activity infringes patent including marketing generic product us patent including sixmonth pediatric extension expires sandoz synthon sun zydus also bound nj district courts decision december tevabarr apotex appealed decision us court appeals federal circuit federal circuit may federal circuit affirmed nj district courts decision june apotex filed petition rehearing en banc denied december united states supreme court denied apotexs petition writ certiorari requesting appeal federal circuit decision concluded matter atripla april teva filed abbreviated new drug application anda manufacture market generic version atripla atripla single tablet threedrug regimen combining companys sustiva gileads truvada time companys us patent rights covering sustivas composition matter method use challenged teva sent gilead paragraph iv certification letter challenging two fifteen orange booklisted patents atripla atripla product joint venture company gilead may gilead filed patent infringement action teva us district court southern district new york sdny january company received notice teva amended anda challenging eight additional orange booklisted patents atripla march company merck sharp dohme corp merck filed patent infringement action teva also sdny relating two us patents claim crystalline polymorph forms efavirenz march gilead filed two patent infringement actions teva sdny relating six orange booklisted patents atripla trial expected possible time reasonably assess outcome lawsuits impact company baraclude august teva filed anda manufacture market generic versions baraclude company received paragraph iv certification letter teva challenging one orange booklisted patent baraclude us patent patent september company filed patent infringement lawsuit us district court district delaware delaware district court teva infringement february delaware district court ruled company invalidated patent company appeal delaware district courts decision evaluating legal options upon final fda approval anda teva could launch generic product could rapid significant negative impact us sales baraclude beginning us net sales baraclude million june company filed patent infringement lawsuit sandoz following receipt paragraph iv certification letter challenging orange book listed patent parties requested case dismissed february parties filed stipulation dismissal case dismissed sprycel september apotex filed anda manufacture market generic versions sprycel company received paragraph iv certification letter apotex challenging four orange book listed patents sprycel including composition matter patent november company filed patent infringement lawsuit nj district court apotex infringement four orange book listed patents covering sprycel triggered automatic month stay approval apotexs anda october company received paragraph iv notice letter apotex informing company seeking approval generic versions mg mg dosage strengths sprycel challenging four orange book listed patents november bms filed patent infringement suit apotex mg mg dosage strengths nj district court case consolidated suit filed november trial currently scheduled september discovery matter ongoing possible time reasonably assess outcome lawsuit impact company sustiva eu january teva obtained european marketing authorization efavirenz teva mg tablets february company merck filed lawsuits requests injunctions teva netherlands germany uk infringement mercks european patent supplementary protection certificates expiring november december requests injunctions granted uk denied netherlands germany company merck appealing denial request injunction netherlands possible time reasonably assess outcome lawsuits impact company general commercial litigation clayworth litigation previously disclosed company together number pharmaceutical manufacturers named defendant action filed california superior court oakland james clayworth et al v bristolmyers squibb company et al alleging defendants conspired fix prices pharmaceuticals agreeing charge drugs us charge outside us particularly canada asserting claims californias cartwright act unfair competition law plaintiffs sought trebled monetary damages injunctive relief relief december court granted company manufacturers motion summary judgment based passon defense judgment entered favor defendants july judgment favor defendants affirmed california court appeals july california supreme court reversed california court appeals judgment matter remanded california superior court proceedings march defendants motion summary judgment granted judgment entered favor defendants plaintiffs appealed decision california court appeals affirmed summary judgment defendants october plaintiffs filed petition seeking review california supreme court denied november remaining apotex matters related plavix previously disclosed november apotex filed lawsuit new jersey superior court entitled apotex inc et al v sanofiaventis et al seeking payment million plus interest calculated rate per month date filing lawsuit paid related breakup march proposed settlement agreement relating thethen pending plavix patent litigation apotex april new jersey superior court granted companys crossmotion summary judgment motion denied apotexs motion summary judgment apotex appealed decisions new jersey appellate division reversed grant summary judgments case remanded back superior court additional proceedings possible time reasonably assess outcome lawsuit impact company january apotex filed lawsuit florida state court broward county alleging breach contract relating may proposed settlement agreement apotex relating pending plavix patent litigation apotex seeking damages amount profits alleges would received selling generic clopidogrel bisulfate somewhere months may agreement approved regulators discovery concluded company moved summary judgment denied november case scheduled trial beginning march possible time reasonably assess outcome lawsuit impact company pricing sales promotional practices litigation investigations abilify federal subpoena january company received subpoena united states attorneys office southern district new york requesting information related among things sales marketing abilify possible time assess outcome matter potential impact company abilify state attorneys general investigation march company received letter delaware attorney generals office advising multistate coalition investigating whether certain abilify marketing practices violated respective states consumer protection statutes possible time reasonably assess outcome investigation potential impact company abilify copay assistance litigation march company partner otsuka named codefendants putative class action lawsuit filed union health welfare funds sdny plaintiffs challenging legality abilify copay assistance program federal antitrust racketeer influenced corrupt organizations laws seeking damages company otsuka filed motion dismiss complaint possible time reasonably assess outcome litigation potential impact company awp litigation previously disclosed company together number pharmaceutical manufacturers defendant number private class actions well suits brought attorneys general various states actions plaintiffs allege defendants caused average wholesale prices awps products inflated thereby injuring government programs entities persons reimbursed prescription drugs based awps company remains defendant two state attorneys general suits pending state courts around country settled lawsuits brought mississippi louisiana attorneys general beginning august company defendant trial commonwealth court pennsylvania commonwealth court brought commonwealth pennsylvania september jury issued verdict company finding company liable fraudulent negligent misrepresentation however commonwealth court judge issued decision pennsylvania consumer protection claim go jury finding company liable million enjoining company contributing provision inflated awps company moved vacate decision commonwealth moved judgment notwithstanding verdict commonwealth court denied company appealed decision pennsylvania supreme court qui tam litigation march company served unsealed qui tam complaint filed three former sales representatives california superior court county los angeles california department insurance elected intervene lawsuit complaint alleges company paid kickbacks california providers pharmacies violation california insurance frauds prevention act cal ins code discovery ongoing possible time reasonably assess outcome lawsuit impact company product liability litigation company party various product liability lawsuits previously disclosed addition lawsuits company also faces unfiled claims involving products plavix previously disclosed company certain affiliates sanofi defendants number individual lawsuits various state federal courts claiming personal injury damage allegedly sustained using plavix currently claims filed state federal courts various states including california illinois new jersey new york defendants terminated previously disclosed tolling agreement effective september february judicial panel multidistrict litigation granted company sanofis motion establish multidistrict litigation coordinate federal pretrial proceedings plavix product liability related cases possible time reasonably assess outcome lawsuits potential impact company reglan company one number defendants numerous lawsuits behalf approximately plaintiffs claiming personal injury allegedly sustained using reglan another brand generic drug metoclopramide product indicated gastroesophageal reflux certain gastrointestinal disorders company generic subsidiary apothecon inc distributed metoclopramide tablets manufactured another party possible time reasonably assess outcome lawsuits potential impact company resolution pending lawsuits expected material impact company hormone replacement therapy company one number defendants masstort litigation plaintiffs allege among things various hormone therapy products including hormone therapy products formerly manufactured company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clots cardiac injuries women defendants aware risks failed warn consumers company agreed resolve claims approximately plaintiffs february company remains defendant approximately actively pending lawsuits federal state courts throughout us companys hormone therapy products sold companies january august resolution remaining lawsuits expected material impact company byetta bydureon amylin whollyowned subsidiary company see note acquisitions lilly codefendants product liability litigation related byetta bydureon february approximately separate lawsuits pending behalf approximately plaintiffs various courts us vast majority cases brought individuals allege personal injury sustained using byetta primarily pancreatitis cases claiming alleged wrongful death company agreed principle resolve claims plaintiffs majority cases pending california state court judicial council granted amylins petition coordinated proceeding california state court cases alleging harm alleged use byetta amylin lilly currently scheduled trial one singleplaintiff case second quarter reasonably predict outcome lawsuit claim proceeding however given amylin product liability insurance coverage existing claims future related claims involving byetta expected amount damages material company bms august company announced discontinued development bms investigational compound tested clinical trials treat hepatitis c virus infection due emergence serious safety issue date five lawsuits filed company texas state court plaintiffs removed federal court alleging participated phase ii study bms suffered injuries result thereof agreement principle resolve four five filed claims vast majority claims surfaced date matter total slightly fewer patients administered compound various doses durations part clinical trials resolution remaining lawsuit potential future lawsuits expected material impact company environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including comprehensive environmental response compensation liability act cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated thirdparties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable company estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties new brunswick facility environmental personal injury lawsuits since may lawsuits filed company new jersey superior court behalf current former residents new brunswick new jersey live lived adjacent companys new brunswick facility complaints either allege various personal injuries damages resulting alleged soil groundwater contamination property stemming historical operations new brunswick facility claims medical monitoring portion complaints also assert claims alleged property damage october new jersey supreme court granted mass tort status cases transferred new jersey superior court atlantic county centralized case management purposes company intends defend vigorously litigation discovery ongoing since october additional cases filed new jersey superior court removed company united states district court district new jersey possible time reasonably assess outcome lawsuits potential impact company north brunswick township board education previously disclosed october company contacted counsel representing north brunswick nj board education boe regarding site waste materials er squibb sons may disposed fill material containing industrial waste heavy metals excess residential standards discovered expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas january new jersey department environmental protection njdep sent company others information request letter possible waste disposal site company responded march boe township current owners school property park conducting jointly financing soil remediation work ground water investigation work work plan approved njdep asked company contribute cost company actively monitoring cleanup project including costs date neither school board township asserted claim company instead company local entities negotiated agreement attempt resolve matter informal means avoid litigation central component agreement provision company interim funding help defray cleanup costs assure work interrupted company transmitted interim funding payments december november parties commenced mediation late however efforts successful parties moved binding allocation process parties expected conduct fact expert discovery followed formal evidentiary hearings written argument hearings likely scheduled midtolate addition september township boe filed suits several parties alleged contributed waste materials site company currently believe responsible additional amounts beyond two interim payments totaling million already transmitted additional possible loss expected material proceedings italy investigation july public prosecutor florence italy italian prosecutor initiated criminal investigation companys subsidiary italy bms italy allegations company relate alleged activities former employee left company italian prosecutor also requested interim measures judicial administrator appointed temporarily run operations bms italy october parties reached agreement resolve request interim measures resulted italian prosecutor withdrawing request request accepted florence court possible time assess outcome underlying investigation potential impact company sec germany investigation october sec informed company begun formal inquiry activities certain companys german pharmaceutical subsidiaries employees andor agents secs inquiry encompasses matters formerly investigation german prosecutor munich germany since resolved company understands inquiry concerns potential violations foreign corrupt practices act fcpa company cooperating sec fcpa investigation march company received subpoena sec subpoena issued connection investigation fcpa primarily relates sales marketing practices various countries company cooperating government investigation matters note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin net earningsloss net earningsloss attributable noncontrolling interest bms earningsloss per share basic earningsloss per share diluted cash dividends declared per common share cash cash equivalents marketable securities total assets longterm debt equity dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin net earnings net earnings attributable noncontrolling interest bms earnings per share basic earnings per share diluted cash dividends declared per common share cash cash equivalents marketable securities total assets longterm debt equity earnings per share quarters may add amounts year period computed discrete basis marketable securities includes current noncurrent assets also includes current portion longterm debt following specified items affected comparability results first second third fourth dollars millions quarter quarter quarter quarter year accelerated depreciation asset impairment shutdown costs amortization acquired amylin intangible assets amortization amylin collaboration proceeds amortization amylin inventory adjustment stock compensation accelerated vesting amylin awards process standardization implementation costs upfront milestone licensing payments iprd impairment impairment charge bms intangible asset provision restructuring pension curtailments settlements gain sale product lines businesses assets litigation chargesrecoveries acquisitionrelated expenses outlicensed intangible asset impairment loss debt repurchases total income taxtax benefit items specified tax benefit increasedecrease net earnings first second third fourth dollars millions quarter quarter quarter quarter year accelerated depreciation asset impairment shutdown costs pension curtailments settlements process standardization implementation costs provision restructuring litigation chargesrecoveries gain sale product lines businesses assets upfront milestone licensing paymentsreceipts iprd impairment total income tax benefit items specified tax benefit decrease net earnings specified tax benefit relates capital loss deduction specified tax benefit relates releases tax reserves specified prior periods note subsequent events collaboration medicines company february bms medicines company entered global license two year collaboration regarding recothrom recombinant thrombin use topical hemostat control nonarterial bleeding surgical procedures previously acquired bms connection acquisition zymogenetics net sales recothrom million connection collaboration medicines company responsible sales distribution marketing certain regulatory matters relating recothrom bms responsible exclusive supply product certain assets transferred medicines company start collaboration period primarily recothrom business license agreement regulatory assets bms retained assets related recothrom including patents trademarks inventory collaboration expires february time medicines company right purchase remaining assets business held bms price determined based multiple sales plus cost remaining inventory held bms time option exercised assets previously transferred medicines company collaboration period revert back bms bms received million start collaboration period allocated license rights transferred medicines company written option recorded option liability fair value allocation based estimated fair value elements considering various market factors estimated excess fair value business potential purchase price option purchase exercised changes estimated fair value option liability recognized results operations remaining amount proceeds received upon entering collaboration recognized alliance revenue throughout term collaboration bms also recognize alliance revenue collaboration period tiered royalties supply product bms provide certain information technology regulatory order processing distribution transitional services exchange fee period six months commencing start collaboration agreement enter collaboration reckitt benckiser group plc february bms reckitt benckiser group plc rbl agreed enter license three year collaboration regarding several overthecounterproducts sold primarily mexico brazil transaction expected close first second quarter subject customary closing conditions regulatory approvals net sales products approximately million connection collaboration rbl responsible sales distribution marketing certain regulatory matters bms responsible exclusive supply products certain limited assets expected transferred rbl start collaboration period primarily market authorization well employees directly attributed business bms retain assets related business including patents trademarks inventory collaboration period upon expiration collaboration rbl right purchase remaining assets business held bms price determined based multiple sales plus cost remaining inventory held bms time option exercised assets previously transferred rbl collaboration period revert back bms bms expected receive proceeds million start collaboration period allocated license rights transferred rbl written option recorded option liability fair value allocation based estimated fair value elements considering various market factors changes estimated fair value option liability recognized results operations remaining amount proceeds received upon entering collaboration recognized alliance revenue throughout term collaboration bms also recognize alliance revenue collaboration period tiered royalties supply product bms also provide certain information technology regulatory order processing distribution transitional services exchange fee period six months commencing start collaboration report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income cash flows three years period ended december financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also audited accordance standards public company accounting oversight board united states companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion companys internal control financial reporting deloitte touche llp parsippany new jersey february item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission permitted sec guidance excluded amylin managements assessment internal control financial reporting december amylins financial statement amounts constituted total assets including billion acquired developed technology rights inprocess research development total net sales companys consolidated financial statement amounts pretax loss million year ended december based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting august bristolmyers squibb company company completed acquisition amylin pharmaceuticals inc amylin represents material change internal control financial reporting since managements last assessment effectiveness amylins operations utilize separate information accounting systems processes possible complete evaluation review internal controls financial reporting since completion acquisition management intends complete assessment effectiveness internal control financial reporting amylin within one year acquisition date changes internal control financial reporting fourth quarter reasonably likely materially affect companys internal control financial reporting item b information none report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission described managements report internal control financial reporting management excluded assessment internal control financial reporting amylin pharmaceuticals inc amylin acquired august whose financial statement amounts constitute total assets including billion acquired developed technology rights inprocess research development total net sales companys consolidated financial statement amounts pretax loss million year ended december accordingly audit include internal control financial reporting amylin companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements year ended december company report dated february expressed unqualified opinion consolidated financial statements deloitte touche llp parsippany new jersey february part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item part iv item